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ABSTRACT 
 
Kristin Lindsey Woo, Ph.D. 
R.N. Adams Institute for Bioanalytical Chemistry 
Department of Chemistry, December 2007 
University of Kansas 
 
 
 Microdialysis sampling is a technique used extensively to monitor analytes 
within numerous tissues.  Although the capability of implanting multiple probes into 
a single animal exists, typical experiments are performed using a single probe.  When 
sampling from heterogeneous tissues (e.g. the stomach), differences between each 
tissue layer cannot be determined by sampling from one probe.  Microdialysis probes 
implanted into each layer would better represent sampling in the stomach.   
The focus of this research was to develop multiple probe microdialysis 
sampling techniques to simultaneously sample different tissue layers of the stomach.  
Furthermore, to augment the application of this approach, multiple probe 
microdialysis sampling was developed to compare different tissue types (i.e. diseased 
and healthy tissue in the same stomach).   
 Initially, methods of probe implantation simultaneously in the lumen, mucosa, 
submucosa and the blood of a rat were developed.  Histology confirmed that 
microdialysis probes were successfully implanted in both the mucosa and submucosa.  
Alternatively, to compare normal and ulcerated tissue, methods of multiple probe 
microdialysis sampling in the lumen, submucosa of ulcerated and normal tissue and 
in blood were developed.  Methods of gastric ulcer induction were optimized and 
 iii
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probes were successfully implanted into the ulcerated and normal tissue, with probe 
location confirmed through histology. 
 To determine the significance of a multiple probe approach, this method was 
used to monitor drug absorption in both normal and ulcerated stomachs.  
Concentration-time curves and pharmacokinetics analyses were performed to 
determine differences in drug concentrations from each probe location.  Results from 
dosed test compounds were determined to be comparable with predicted absorption 
rates.  Differences in drug concentration were observed between the mucosa and 
submucosa and increased concentrations were determined in ulcerated relative to 
normal tissue. 
 Overall, the research presented illustrates that microdialysis probes can be 
successfully implanted in different stomach tissue layers simultaneously and that this 
approach can be used to monitor different tissue layers in the stomach as well as 
directly compare ulcerated and normal tissue.  A multiple probe approach serves as 
improvements to current uses of microdialysis sampling in the stomach as well as 
traditional sampling methods to measure drug absorption in the GI tract. 
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CHAPTER ONE 
 
Introduction to Microdialysis Sampling and Drug Absorption  
in the Gastrointestinal (GI) Tract 
 
 
1.1 Drug Development and Delivery 
 
 The 2006 National Center for Health Statistics Report stated that an average 
of 1.7 drugs were ordered or provided to patients per physician visit and that 
collectively, 1.6 billion drugs were ordered or provided by physicians offices in 2004 
[1].  With this high demand for medications, development of new and existing 
pharmaceuticals continues to be an ongoing and important aspect for pharmaceutical 
companies.  However, the development of pharmaceuticals is an arduous task.  Not 
only does the drug need to have the chemical properties necessary to interact with 
specific receptors at the site of action and create a therapeutic effect, the drug must 
also be able to reach the target site when introduced into the body [2].  The amount of 
drug, typically measured by the extent of absorption into the systemic circulation, that 
is accessible for a therapeutic effect is called drug bioavailability [3].  Plots of drug 
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concentration in the plasma with respect to time are generated to assess 
bioavailability.  Figure 1.1 is a representation of a plot of concentration versus time 
[2].   Bioavailability is determined by measuring the area under the curve (AUC) of 
the concentration versus time plot [2].  These plots are also useful to determine the 
time of drug onset in the plasma and the duration of drug concentration in the 
therapeutic range (i.e. concentrations above the minimum effective concentration 
(MEC) and below the minimum toxic concentration (MTC)).  
 Blood sampling is carried out to determine drug bioavailability since 
measurements of drug concentration at the target site are not practical in a clinical 
setting.  It is generally assumed that the drug concentration at the target site is in 
equilibrium with the blood since the bloodstream is the carrier of drug to the target 
site [3].  Although blood sampling is useful in the determination of overall absorption 
into the bloodstream, drug concentrations at the site of absorption and at the target 
site of action cannot be assessed from blood sampling alone.  Several methods have 
been developed in attempts to further monitor the site of absorption and drug 
concentrations at the target site, which will be discussed further in this chapter. 
  
1.1.1   Routes of Administration 
 The formulation of the drug and the route of drug administration are key 
components that can alter drug distribution, the onset of drug appearance 
systemically, the concentration of drug available and the duration of the drug in the 
therapeutic range [2].  The route of administration is the method in which a drug is 
 2
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 Figure 1.1.  Schematic of drug concentration in plasma versus time.  
MEC is the minimum effective concentration and MTC is the minimum 
toxic concentration [2]. 
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 introduced to the body.  There are numerous ways to administer a drug, which can be 
grouped into two categories:  invasive and non-invasive.   
 Invasive techniques are parenteral routes of administration, including 
intravenous, intramuscular and subcutaneous.  Drugs delivered by these routes are 
directly injected into the blood, muscle or subcutaneous layer.  Intravenous 
administration has complete bioavailability since it is directly injected into the 
bloodstream and no absorption needs to occur.  In intramuscular or subcutaneous 
administration, drug must diffuse through the muscle layer or connective and adipose 
tissues, respectively.  However, neither needs to cross a biological barrier to be 
bioavailable.  As drug diffuses across these tissue layers, some drug may be subjected 
to metabolism and degradation.  Therefore, intramuscular and subcutaneous 
injections have a later onset than intravenous administration and may have lower 
bioavailability.  Moreover, parenteral routes are not only invasive, but injection of 
drugs via a hypodermic needle punctured through the skin is unfavorable for most 
patients.  This is the basis of trypanophobia (i.e. needle phobia), which can result in 
patient avoidance of crucial medical treatments completely [4].  In addition to this 
route of administration resulting in poor patient compliance, it typically requires a 
skilled person for dosing to ensure the injection is made to the correct area, especially 
for intravenous administration [3].   
 Non-invasive techniques are any route of administration that does not involve 
injection of the drug.  These are routes such as enteral (e.g. oral, sublingual and 
suppositories), transdermal and pulmonary routes.  Dosing by these routes of 
 4
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administration can be more difficult because drugs must cross a biological barrier in 
order to be bioavailable [3].  In the case of enteral routes, the gastrointestinal (GI) 
tract poses a barrier to drug delivery, while the skin is the barrier for transdermal 
delivery and the lungs create a barrier for pulmonary delivery of drugs.  There are 
several formulations and routes to administer a drug to the body that need to be 
considered during drug development in order to achieve higher bioavailability.  
 Figure 1.2 shows the concentration-time curves for invasive and non-invasive 
routes of administration, intravenous and oral, respectively [3].  These two routes 
have distinct curves corresponding to different times of onset, intensity and duration 
in the therapeutic range. Due to complete bioavailability (no absorption phase) with 
intravenous administration, the intensity of the drug in the therapeutic range is higher 
than the oral route of administration.  Intravenous administration also has a fast time 
of onset, whereas delays may be observed due to slow absorption from oral dosing.  
These curves are typical results expected from comparing routes of administration.  
For example, studies of the effects of route of administration of aspirin show a 68% 
decrease in bioavailability in oral dosing relative to intravenous dosing in the rabbit 
[5] and a 57% decrease from oral dosing in comparison to intravenous administration 
in humans [6].  In addition, the bioavailability of an intramuscular dose of aspirin was 
89% that of an intravenous dose in humans [7].  Bioavailability from the oral and 
intramuscular dose in these studies was determined by comparison of plasma 
concentrations to the equivalent intravenous dose, which is assumed to be complete 
since the drug is administered directly to the bloodstream.  This is the common
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Figure 1.2.  Plot of drug concentration in plasma versus time for  
intravenous (      ) and oral (----) routes of drug administration [3]. 
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method to quantify relative bioavailability for routes of administration other than 
intravenous [2].   
 
1.1.2   Drug Administration by Oral Dosing 
 Despite the documented difficulties of drug absorption and the decreased 
bioavailability from oral dosing, this route of administration continues to be the 
preferred route by both physicians and patients because of the non-invasive nature of 
administration and good patient compliance.  An estimated 90% of medications are 
given as oral doses, making oral formulations a major focus in drug development [3].  
However, as will be discussed in the next section, the GI tract has many unfavorable 
conditions for drug absorption making oral drug delivery very challenging. 
 
1.2   Drug Absorption in the GI Tract 
  
1.2.1   Anatomy of the GI Tract 
 The GI tract starts at the mouth and ends at the rectum with several segments 
in-between as shown in Figure 1.3 [8].  Each segment of the GI tract serves a 
different function.  The primary function of the mouth is to start digestion by 
breaking materials into smaller pieces.  The esophagus connects the mouth to the 
stomach; however, because of the fast transit time of materials through the esophagus, 
the esophagus is not involved in the digestive process itself.  The stomach is mainly a 
digestive organ, but for oral dosing, the stomach is the first area of possible
 Esophagus 
Stomach 
Small 
Intestines 
Large 
Intestines 
Figure 1.3.  Schematic of the GI tract.  Reproduced from 
www.gicancertrials.org.au/GENERAL/images/stomach.gif 
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significant drug absorption [9,10].  The reasons for this will be discussed in Section 
1.2.4.  The stomach is connected to the duodenum, the first part of the small 
intestines, where most absorption occurs.  Absorption continues through the jejunum 
and the ileum, the remaining sections of the small intestines.  The small intestines 
connect to the large intestines, where material is prepared for excretion from the 
rectum. 
 The tissue of the GI tract is heterogeneous with several layers.  Figure 1.4 
shows the tissue layers of the stomach [3,8].  Although there are differences in cell 
type and organization within the different segments of the GI tract, there are four 
basic layers common to all segments of the GI tract [8].  The lumen is the inner 
cavity, which holds unabsorbed material, mucus and GI solution.  The mucosa is the 
innermost tissue layer throughout the GI tract.  It consists of a monolayer of cells 
supported by the lamina propria and muscularis mucosa.  The next layer is the 
submucosa, a layer of connective tissue, which houses the major blood vessels, 
lymphatics and nerves in the GI tract and, therefore, is the site of the majority of 
systemic absorption.  The muscularis externa is a muscle layer that acts as an outer 
supporting wall and contributes to peristalsis throughout the GI tract.  The serosa (not 
shown in Figure 1.4) is the outermost layer and is a thin sheath comprised of 
connective tissue [8,11].  
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Figure 1.4.  Tissue layers of the stomach.  1- Lumen; 2- Mucosa;  
3- Submucosa and 4- Muscularis Externa.  Reproduced from 
www.echomedicalmedia.com/anat07.html
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1.2.2   GI Disease: Ulcers 
 Affecting approximately 15% of the population in the United States, ulcers are 
one of the most prevalent diseases of the stomach and duodenum [12].  Variable 
frequencies of ulceration have been reported for other countries with a high 
prevalence in developing countries [12,13].  Ulcers are formed by the erosion of the 
mucosa layer [14].  Commonly, this erosion is ≥ 3 mm in length in humans [12].  
Without the protective mucosa layer present, the underlying submucosa is subjected 
to the harsh environment of the lumen.  For instance, in the stomach, the low pH and 
luminal flora in the lumen cause further damage to the stomach tissue once the 
mucosa is compromised.  The continued degradation of the mucosa and submucosa 
can result in perforation of the GI tissue, leading to more serious, life-threatening 
conditions such as peritonitis [14].  Typically, multiple ulcers form concurrently 
adding to the severity of the disease.  Figure 1.5 is a schematic of a gastric (stomach) 
ulcer.   
 Helicobacter pylori and non-steroidal anti-inflammatory drugs (NSAIDs) 
have been identified as the two main ulcer causing agents [14,15].  H. pylori infection 
has been the reported source of 75% of gastric ulcers and 90% of duodenal ulcers 
[12,16].  However, ulceration has been shown to be further aggravated by other 
factors such as stress, smoking, alcohol and coffee beverages, delayed gastric 
emptying and bile reflux [12,15].  Successful eradication of H. pylori, most 
commonly achieved by proton pump inhibitors (PPIs) based therapy, has been shown 
to be effective in the majority of ulcer treatments [17].  However, ulcer relapse and 
  
Figure 1.5.  Schematic of a gastric ulcer.  Reproduced from 
http://hopkinsgi.nts.jhu.edu/images/shared/disease/ 
database/shared_327_PU-04.jpg 
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exacerbation has been reported, especially in patients on long-term low-dose aspirin 
or other NSAIDs for treatment of arthritis, for cardiovascular protection, or for 
general pain and inflammation reduction [18,19].   
 
1.2.3   Mechanisms of Drug Absorption 
 The general theory on absorption through the GI tissue is that the majority of 
absorption occurs by passive diffusion [3].  By passive diffusion, drug uptake through 
the mucosa layer is driven by a concentration gradient.  The rate of passive diffusion 
can be described by Fick’s First Law: 
 
    
dx
dC -D Jx =       (1) 
 
where Jx is the flux, D is the diffusion coefficient and dC/dx is the concentration 
change over a distance x [2,3].  This equation illustrates that diffusion across a 
membrane is based on a concentration gradient, and so continued diffusion will 
depend upon the rate at which the diffused drug is transported away from the 
membrane, as well as drug concentration on both sides of the membrane.  There are 
two mechanisms of passive diffusion, transcellular (through the cell) and paracellular 
(between adjacent cells).  Molecules taken up transcellularly are limited by the lipid 
cell membrane and the lipid/water interface on the surface of the membrane.  
Therefore, only small, lipophilic compounds will typically transport across the 
mucosa cells through a transcellular pathway [2,3].  Paracellular transport can be 
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hindered by junction complexes between the cells.  These junction complexes, made 
of binding proteins and filamentous matter, basically bind the cells near the apical 
side and protect luminal contents from entering in-between the cells and limiting 
transport to small, hydrophilic molecules transport [2,3].  Although passive diffusion 
is mostly limited to small molecules (< 500 Da), several reports have suggested that 
paracellular transport of some polypeptides (4000 Da) across the intestinal epithelium 
is possible [20]. 
 Besides passive diffusion, transport across the GI mucosa can occur by 
carrier-mediated processes.  In this type of transport, membrane proteins, either on 
the cell surface or that span the entire membrane, can complex with molecules and 
transport them across the cell membrane [2,3].  Carrier-mediated processes can occur 
with (facilitated transport) or against (active transport) a concentration gradient.  Both 
facilitated and active transport requires energy from ATP hydrolysis in order to 
transport molecules across cellular membranes [2,3,21].   
 Figure 1.6 shows a schematic of the major different modes of transport across 
a cell membrane in the stomach [3,8].   Normally, transport across the cell occurs 
from the apical (top of the cell) surface to the basolateral (bottom of the cell) surface.  
In normal cellular processes, both passive diffusion and carrier-mediated modes 
transport drugs across cellular membranes, with modes of passive transport being the 
primary ones since they no not require energy to transport molecules.  Typically 
transport occurs by a primary mechanism; however, alternative mechanisms can act 
in conjunction with the primary mode [11,22].   
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1 2 3 
Apical 
Basolateral 
Figure 1.6.  Mechanisms of transport across gastric mucous cells.   
1- Transcellular passive transport; 2-Paracellular passive transport and 
3-Carrier-mediated active transport [3,8]. 
 15
1.2.4   Factors Affecting GI Drug Absorption 
1.2.4.1   Normal Anatomical and Physiological Factors  
 There are many factors that affect when and where drugs will be absorbed in 
the GI tract.  Anatomical and physiological factors of the GI tract greatly influence 
absorption and make oral drug delivery an extremely variable route of administration 
[21].  Most segments of the GI tract have folds in the mucosa layer to increase surface 
area and to make room for passing materials.  The majority of absorption occurs in 
the small intestines because it has the most folds in the mucosa layer and also because 
the mucosa has microvilli.  The mobility of passing material and transit time, in 
addition to the amount of time the materials are exposed to the surface of each 
segment in the GI tract, will affect the absorption.  Table 1.1 lists the typical transit 
times in the human GI tract [23].    
 Bacteria, enzymes and food present in the lumen alter absorption, making 
prediction of the location of drug absorption more problematic.  Bacteria and 
enzymes can act on drugs and degrade them before they are absorbed. The presence 
of food in the stomach creates changes including in pH, viscosity of luminal solution 
and, especially, changes in gastric emptying [24]. In general, food has been shown to 
increase gastric emptying, decreasing drug exposure to the stomach surface and 
ultimately decreasing drug absorption [11,23].  Studies have reported that oral drug 
administration in fed states has been shown to cause a decrease in drug absorption 
relative to fasted states [25-27].  However, increases [27] or no change in absorption 
[27-29] have also been observed for several drugs despite the expected trend that food 
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causes decreased absorption.  In addition to altering gastric emptying, drugs can 
adsorb to food in the lumen, which can further delay or decrease drug bioavailability 
[21].   
 The pH is different in each segment of the GI tract.  There is a pH gradient 
from the stomach to the large intestines, which is illustrated in Table 1.1 [11].  The 
effects of the different pH levels on drug absorption will be further discussed in the 
next section. 
 
  Transit Time pH 
Esophagus 5-15 seconds 5-6 
Stomach 0.5-1 hour 1-3 
Small Intestines 3-5 hours 5-6 
Large Intestines 5-7 hours 7 
 
 
 
 
 
Table 1.1.  Transit times and pH values for the different 
segments in the GI tract. 
 
 
 
Along with transit times, pH levels and luminal flora, the mucosa is lined with 
a stagnant, aqueous layer adjacent to the epithelial cells that can impede uptake of 
drugs [21].  This viscous layer consists mostly of water, mucus and mucins where, in 
particular, drugs of large molecular weight or poor aqueous solubility have limited 
permeability into the mucosa [11]. The function of this layer is to protect the GI tissue 
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from destructive components (i.e. luminal pH, food, alcohol, microorganisms) and 
also to hydrate the GI tissue.  In addition to selectively impeding large molecular 
weight and highly lipophilic compounds, drugs can complex with stagnant layer 
matrix components further prohibiting uptake of drugs [21].  As mentioned above, 
one of the functions of this aqueous layer is to protect the GI tissue from the luminal 
pH.  This is particularly important in the stomach, where the pH is very low, as was 
shown in Table 1.1.  The stagnant aqueous layer impedes movement of hydrogen 
cations to the mucosa layer.  At the same time, the mucous epithelial cells of the 
mucosa secrete bicarbonate into the stagnant layer.  This creates a pH gradient within 
the stagnant layer with low pH closer to the luminal side of the stagnant layer and 
near neutral pH next to the mucosa [21].  For drug absorption, the microclimate of the 
stagnant aqueous layer needs to be considered.  Studies have indicated that for most 
compounds, the layer is insignificant for overall absorption [30,31]; however, some 
dependence of this layer on absorption has been reported (e.g. for digoxin and 
quinidine) [32,33]. 
1.2.4.2   Physicochemical Properties and Drug Formulation 
 Physicochemical properties of the drug and its formulation are important 
factors in affecting the extent and location of drug absorption.  The conventional 
formulations for oral drug delivery include: solutions, suspensions, capsules, and 
tablets [11].  Dissolution of the drug is required prior to absorption for all of the 
formulations except solutions.  The dissolution rate of the drug is typically the rate- 
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limiting step for oral dosing and is described by the Noyes Whitney equation: 
 
             - C)(C
h
DA
dt
dC
s  =                 (2) 
 
where dC/dt is the rate of dissolution, D is the diffusion rate constant, A is the particle 
surface area, h is the stagnant layer thickness and Cs and C are the concentrations of 
drug in the stagnant layer and the bulk solution, respectively [2].   The stagnant layer 
results from the saturation of drug in solution at the surface of the drug particle during 
dissolution.  The drug diffuses to bulk solution once it passes the stagnant layer 
adjacent to the particle.  Along with a concentration gradient, this equation describes 
that dissolution is driven by surface area.  Smaller particles have more surface area to 
the dissolving solution, which results in a faster dissolution rate [11]. 
   The drug not only needs to have good aqueous solubility for dissolution, the 
compound also needs good lipid solubility to permeate the mucosa barrier.  Lipid 
solubility is predicted from the drug partition coefficient (P): 
 
             
water
oil
C
C P =                  (3) 
 
where the concentration of drug (C) is measured in two immiscible liquids at 
equilibrium to determine the partitioning of drug between the lipophilic and aqueous 
phases [3].  Drugs with positive log P values have higher lipid solubility and are more 
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likely to permeate the mucosa barrier in comparison to compounds with negative log 
P values, which exhibit lower lipid solubility. For ionizable compounds, log P is 
affected by pH.  Therefore, the distribution coefficient (D) is used to determine drug 
lipophilicity for ionizable compounds.  Partition coefficients and distribution 
coefficients are related by the equation: 
 
          α)P(D −= 1                  (4) 
 
where α is the degree of ionization.  This equation indicates that the distribution 
coefficient is the partition coefficient of the fraction of unionized drug at a given pH 
[3]. 
  According to the pH partition hypothesis, drugs in an unionized form will 
passively diffuse through the mucosal barrier [11,21].  The degree of ionization is 
described by the Henderson-Hasselbach equation, which relates pH, pKa and the ratio 
of the concentrations of the ionized form of the drug to the unionized form [3,21].   
 
          For weak acids:                          
[HA]
][Alog  pK  pH
-
a +=                (5) 
 
          For weak bases:                        
][BH
[B]log  pK  pH a ++=                   (6) 
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As shown above in Table 1.1, in the stomach, the luminal pH is around 1-3.  In 
general, weakly acidic drugs will be neutral and weakly basic drugs will be charged 
when protonated in this acidic environment.  Therefore, based on the pH-partition 
hypothesis, weakly acidic drugs can be absorbed in the stomach whereas most weakly 
basic drugs would not be absorbed. 
 Overall, the physicochemical properties of the drug in combination with the 
anatomical and physiological factors can make drug absorption in the GI tract 
difficult to predict.  Therefore, methods to monitor the location and extent of 
absorption would be useful for drug development studies. 
1.2.4.3   GI Disease Effects 
 Diseases in the GI tract can alter the anatomy and physiology of the GI tissue 
by affecting mobility, pH levels and mucosal tissue integrity caused by atrophy 
[34,35].  Therefore, bioavailability of orally dosed drugs may be altered as a result of 
disease.  In the case of ulcerated tissues, as described earlier in Section 1.2.2, the 
mucosa barrier that is normally selective for absorption is absent.  Therefore, 
increased and non-selective absorption through the GI tissue occurs.  For example, 
Tur et al. studied the absorption of phenol red, normally a non-absorbed compound in 
the rat stomach, in both normal and ulcerated rat stomach after oral administration.  
Urine analysis for phenol red showed a 3-fold increase in overall absorption of phenol 
red in ulcerated relative to normal stomach [36].  The results from this study are an 
example of both drug absorption enhancement and decreased selectivity in absorption 
in ulcerated tissue. 
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 Even though overall bioavailability has been shown to be enhanced in 
diseased states, most studies of drug absorption and bioavailability are performed on 
healthy, normal subjects [37].   Dose adjustments may be needed to account for this 
increased bioavailability in patients with GI diseases.  Methods to understand drug 
absorption in diseased states and also the biological mechanisms that change in 
disease will help the development of dose adjustments of pharmaceuticals. 
 
1.3   Methods to Study GI Tract Drug Absorption 
 
1.3.1   In Vitro Permeability Studies  
 Drug absorption in the GI tract has been studied by several in vitro and in vivo 
methods. In vitro methods can be easily performed in place of in vivo models to 
rapidly screen GI absorption of potential drug candidates or in order to study specific 
events that can be difficult to monitor due to the complexity of biological systems. 
Three commonly used in vitro models for GI drug absorption are described below.  
1.3.1.1   Cell Culture Models 
 Cell culture models are widely used to rapidly screen potential candidates in 
drug development.  The most commonly used system for studies in the GI tract is 
Caco-2 cell monolayers [22,38,39].  These cells are derived from the human 
colorectal carcinoma cell line [39].  Although from the colon by nature, Caco-2 cells 
have been shown to exhibit the morphological and physiological behaviors of 
intestinal absorptive cells [38].  Of particular importance is the ability of these cells to 
 22
form tight junctions between cells [38,39].  Tight junctions are a component of the 
junctional complex, described in Section 1.2.3, which are the main barrier in 
paracellular transport.  Therefore, mechanisms of transport other than transcellular 
passive diffusion can be studied with Caco-2 monolayers.  For this method, cells are 
grown on a semi-permeable membrane.  Interestingly, these cells have been shown to 
polarize and form a confluent layer on the membrane [39].  This membrane is placed 
in a diffusion cell with a donor and a receiver chamber.  Drug is applied to the donor 
chamber, typically the apical side of the monolayer, and permeability studies are 
performed by monitoring drug concentrations from both chambers [38,39].  The use 
of cell models such as the Caco-2 line is advantageous as an in vitro technique since 
the cells are derived from human; however, Caco-2 cells have a tumor origin and 
require at least a 2-3 week period for full morphological and functional differentiation 
[38,39].  Other cell lines, such as HT-29 or MDCK cells, have been used as 
alternative monolayers or have been co-cultured with Caco-2 cells for study 
specialization [38].  For instance, HT-29-H and HT-29-MTX cells have been co-
cultured with Caco-2 cells to monitor mucus secretion and to mimic carrier-mediated 
uptake, respectively [38,40]. 
1.3.1.2   Everted Intestinal Sacs 
 The everted intestinal sac has been commonly used as a relatively inexpensive 
and rapid procedure for drug permeability studies in the intestines [39,41,42].  For 
this procedure, the intestines are harvested from the euthanized animal and everted so 
that the mucosa becomes the outer surface of the intestines.  The intestines are 
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clamped at both ends and then filled with solution.  The tissue is then suspended in an 
oxygenated tissue culture.  The drug of interest is dissolved and added to the tissue 
culture.  At the end of the experiment, the tissue is removed from the culture and the 
inner solution is analyzed for drug content.  The drug in this solution represents the 
amount of drug that permeated the intestines.  Variations to this technique have been 
made that include methods of serial sampling and the use of non-everted intestinal 
sacs [42,43].  The everted intestinal sac is a technique to look at absorption through 
an actual segment of the intestines where all cell types are present on the mucosa, 
which is not the case when using cultured cell lines to monitor absorption.  The major 
disadvantages to this method are that there is no blood perfusion to the tissue and that 
drug absorption must occur across the entire tissue, even the muscularis externa and 
serosa.  However, for fast semi-quantitative results, the everted intestinal sac is a 
useful method over other in vitro techniques. 
1.3.1.3   Excised Tissue Permeability Studies: Ussing Chamber 
 The two previously described in vitro techniques of using cell cultured 
monolayers and everted intestinal sacs are limited to studying drug absorption in the 
intestines.  To study absorption in the stomach by in vitro models, excised stomach 
tissue can be mounted into a diffusion chamber by the Ussing Chamber technique 
[44].  The Ussing Chamber was originally designed to monitor ion transport across 
membranes, but variations to this technique have been made to extend its use in drug 
absorption studies [39].  Similar in concept to the cell cultured monolayers, a small 
section of tissue is mounted between two chambers, a donor chamber and receiver 
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chamber.  Drug is placed in the donor chamber and samples are taken from the 
receiving chamber and analyzed for drug permeation across the tissue [38,39].  Like 
the everted intestinal sac method, using excised tissue is advantageous because actual 
tissue that includes the different cell types of the mucosa.  As previously mentioned, 
most tissues can be mounted in the chamber and because of the small sample size 
needed for the chamber (~9 cm2), Caco-2 monolayers and human tissue biopsies have 
been used as well [39,45,46].  As with the everted intestinal sacs, a disadvantage of 
the Ussing Chamber is that it is used to monitor drug absorption across the entire 
tissue, even through the muscularis externa and serosa.  Another drawback is the time 
required to prepare the chamber and perform the procedure, therefore, it is not 
recommended as a rapid screening technique [39,45]. 
 
1.3.2   In Vivo Absorption Studies 
 The disadvantage to in vitro studies is that they do not take into account the 
aforementioned physiological factors that affect drug absorption in the GI tract.  
Therefore, in vivo models are used for a more complete understanding of drug 
absorption in the GI tract.  A number of in vivo models are discussed below. 
1.3.2.1   Blood Sampling  
 Venous blood sampling at timed intervals is by far the most common method 
to monitor drug absorption after an oral dose for in vivo studies [47-51].  This 
involves giving an oral dose to the animal and drawing blood samples post dose.  
However, blood sampling results in overall fluid loss, which can perturb the system 
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under study.  Rodent blood typically takes up to 2 weeks to fully regenerate and it is 
suggested that only 1% of the circulating blood volume (which is 20-25 mL in the rat) 
can be safely removed every 24 hours [52,53].  This limits the temporal resolution 
possible before the volume of blood in the system changes.  For most studies 
involving blood sampling in the rat, volumes of 150-400 µL are withdrawn for each 
time point, exceeding the recommended sampling rate [47,50,51].  Whole blood 
samples have many components that are not amenable with analytical systems and 
need to be removed prior to analysis, resulting in increased analysis time.  A 
conventional sample clean-up procedure for analysis is to collect blood samples into 
heparinized vials to prevent blood clotting.  The vial is centrifuged down and the 
supernatant is drawn up, which is the plasma [47,49,51].  The plasma is further 
prepped for analysis by methods including protein precipitation, solid-phase 
extraction or liquid-liquid extraction [47-49,54].  Efforts to decrease preparation time, 
such as direct injection of plasma samples for analysis by column switching or 
turbulent flow chromatography (TFC), have been developed [54,55].  Although 
decreased temporal resolution and sample pre-treatment are big disadvantages, more 
importantly, results from blood sampling only reflect that the compound was 
absorbed.  Sampling in this manner gives no indication of the location in the GI tract 
from which the drug was absorbed or what concentration of drug is present in the 
tissue.  Tissue homogenate studies by Choi et al. which suggest that salicylic acid 
accumulates in the gut tissue of the intestines after an oral dose is just one example of 
why a more tissue-specific technique is needed [56].  Blood sampling is not sufficient 
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to allow for the site of drug absorption to be located or for the assessment of tissue 
accumulation.  
1.3.2.2   In Situ Closed Loop Animal Studies 
 An in situ closed loop method is another way to monitor drug absorption in 
the GI tract that is more site-specific than blood sampling alone [56,57].  For this 
method, drug in solution is dosed through a cannula to a closed portion of the GI tract 
and absorption is determined by extracting solution from the lumen.  This method 
gives a direct measurement of the lumen, but assumes that any amount of drug not 
present in the lumen was absorbed and does not account for events such as 
degradation nor does it assess what is happening in the tissue of the GI tract.  Also, 
because this method relies on a section of the GI tract to be closed off, this method is 
not capable of further development in conscious animals for extended periods of time.  
In situ closed loop animal studies are therefore very limited both in their application 
and in terms of the information that can be gained from them.  Methods to site-
specifically monitor the location and the extent of absorption in the GI tract would 
serve as an improvement for drug development studies. 
1.3.2.3   Tissue Homogenate Studies 
 Excised tissue studies have been performed to look at the gut tissue directly 
for tissue distribution studies [56,58,59].  At a certain time point post dose, the animal 
is sacrificed and the gut tissue is removed and processed for drug concentration as a 
tissue homogenate.  The concentration determined from the tissue is the total drug 
concentration (protein bound + free, unbound drug).  Typically, the fraction of 
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interest is the free, unbound drug since it is the therapeutically active portion.   
Further analysis is needed to determine the unbound drug concentration.  For a 
complete study, multiple animals are used to monitor drug absorption.  This use of 
several animals in one study causes larger biological variability and therefore, subtle 
changes are more difficult to assess.  Methods to reduce the number of animals used 
would lower biological variability within the study. 
 
1.4   Microdialysis Sampling 
 
 Microdialysis sampling is a tissue-specific technique that has been used for 
decades to monitor drug concentrations directly in targeted tissues for 
pharmacokinetics (PK) studies [60-66].  Microdialysis sampling has been shown to be 
suitable to overcome the shortcomings of the in vivo techniques outlined above.  
Extension of this technique to monitor drug absorption in the GI tract could prove 
beneficial for a more complete understanding of absorption in both normal and 
diseased GI tissues.  
 
1.4.1   Theory and Principles of Microdialysis Sampling 
 Microdialysis sampling is a site-specific technique typically used to sample 
low molecular weight compounds in the extracellular space at a site of interest 
[67,68].  A microdialysis probe consists of a small semi-permeable membrane that is 
implanted into a tissue or site of interest (e.g. the blood) where the probe acts 
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similarly to a blood vessel.  A perfusion fluid, that is isotonic and at the same pH as 
the surrounding environment, is continuously pumped through the probe inlet.  
Typical flow rates through the probe are 1-5 µL/min although lower flow rates can be 
achieved.  Low molecular weight compounds diffuse into and out of the probe based 
on a concentration gradient and are carried by the perfusion fluid to the probe outlet 
for collection.  The collected samples are termed dialysate samples. 
 Microdialysis was first used as a sampling technique in the brain to monitor 
dopamine [69] and the brain has continued to be the most widely studied organ with 
microdialysis.  In addition, implantation of microdialysis probes has been extended to 
basically every tissue [60,62,64-66,70].  Microdialysis sampling has been used to 
look at endogenous compounds before and after an event such as drug dosing as in 
pharmacodynamics (PD) studies and also to look at exogenous compounds for PK 
studies, as previously mentioned. This technique has been used for in vitro and in vivo 
studies mainly in animal studies including anesthetized and awake animals, but 
recently, the use of microdialysis sampling in humans has grown [71-74]. 
1.4.1.1   Microdialysis Probe Designs 
 There are many different probe designs and configurations based on the target 
sampling site.  The main components of a microdialysis probe are inlet and outlet 
tubing and a semi-permeable membrane.  Several materials have been used for the 
semi-membrane.  Some of the most commonly used membrane types are 
polyacrylonitrile, polycarbonate, regenerated cellulose and cellulose acetate [75].  
The choice of membrane is based on membrane composition (charge and 
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hydrophobicity) and on the molecular weight cut off (MWCO) [76].  There are two 
main configurations of microdialysis probes: cannula style and linear.   
 A cannula style probe can be in a concentric or side-by-side fashion.  The 
membrane is slid over the probe inlet and the inlet is placed inside the outlet 
(concentric) or directly next to the outlet (side by side).  These probes are used for 
tissues where increased spatial resolution is needed, such as the brain.  Moreover, 
because of the rigidity of the probe, this style probe is robust enough for awake 
animal studies in the brain.  Although this style probe can be used in other tissues, 
tissue tearing is possible due to the rigidity of the probe [76].  A more flexible 
cannula style probe was designed to implant in tissues, which is used mostly for 
sampling from the blood [77].  Figure 1.7a is a schematic of a flexible cannula style 
probe.  A more in-depth discussion of the flexible style probe construction will be 
presented in the next chapter. 
 Linear probe configurations were designed for use in peripheral tissues [76]. 
The inlet and the outlet are connected to the membrane in a successive fashion.  
Linear probes are flexible and are used for sampling when a cannula style is not 
necessary (i.e. when spatial resolution is not crucial).  Figure 1.7b is a schematic of a 
linear probe.  The construction of linear probes will be discussed in more depth in the 
next chapter.   
Another design, the shunt probe, has been developed for sampling in moving 
fluids, mostly the bile [76].  The design of the probe is similar to a linear probe, but 
the probe is placed inside a larger tube and the tube is implanted (i.e. into the bile 
 30
  
(a) 
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Figure 1.7.  Microdialysis probe designs (a) flexible cannula and (b) linear 
probe designs.  Arrows indicate direction of perfusion fluid flow.  Adapted 
from www.bioanalytical.com. 
(b) 
duct of the liver).  The bile flows freely inside the larger tube where it can be readily 
sampled by the probe [76].   
1.4.1.2   Implantation of Microdialysis Probes 
 Successful microdialysis sampling experimentation is dependent on the probe 
recovery, which in turn, is a factor of several factors including membrane type and 
length, probe geometry, perfusate flow rate and the analyte properties and transport 
across the probe membrane [76].  Furthermore, for successful in vivo microdialysis 
sampling, proper probe implantation techniques are important.  Improper probe 
implantation can cause damage to the microdialysis probe as well as to the target 
tissue.  The required criterion for successful microdialysis probe implantation 
includes a small outer diameter microdialysis probe that will minimize damage to the 
tissue and the probe upon implantation and also surgical procedures that are 
minimally invasive for proper probe implantation [77].   
The conventional method of implantation is by use of some type of cannula or 
introducer, which guides the probe into the tissue and serves to protect the probe 
during implantation into the tissue [67].  The guide cannula is initially inserted into 
the tissue and the microdialysis probe is inserted into the guide cannula.  The cannula 
is subsequently removed, leaving the microdialysis probe in the tissue.  The cannula 
needs to be large enough to house the probe but not too big to cause extensive 
damage to the tissue [77].  Alternately, implantation of a cannula style microdialysis 
probe into peripheral tissue can be achieved by puncturing the tissue with a needle.  
The probe is then inserted into the hole created by the needle [78-80].  Ideally, 
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implantation by this method would cause less damage to the tissue relative to using a 
guide cannula since the guide cannula needs to have a larger diameter than the probe.  
However, this method could result in damage to the probe during implantation due to 
tissue resistance.  This method is not feasible for linear probe implantation since an 
entrance and exit site are needed for probe implantation.   
 Implantation of the probe with minimal tissue perturbation is necessary; 
however, another crucial factor is the controlling of the location of probe 
implantation.  Microdialysis probe implantation into the brain is conventionally 
performed with the use of a stereotaxic frame [63,81].  Because of the precision of the 
stereotaxic frame, highly reproducible implantation procedures can be achieved [82].  
For implantation in peripheral tissues; however, equipment to accurately and 
reproducibly implant guide cannulas into peripheral tissues have not been designed.  
Therefore, implantation into the tissue relies on the precision of the surgeon who is 
implanting the probe.  Implantation into a homogenous tissue, such as the liver, is not 
surgically complicated since the tissue type is the same throughout [83].  When the 
tissue is heterogeneous (i.e. has several tissue layers within the tissue) implantation 
into separate layers is more difficult to control and reproduce because of the 
limitations that the tissue layer thickness imposes.  As described in Section 1.2.1, the 
stomach tissue is heterogeneous mainly consisting of a mucosa, submucosa and 
muscularis externa layer.  Proper microdialysis probe implantation is crucial in order 
to keep the probe from penetrating into the adjacent tissue layer.  For example, 
improper probe implantation in the stomach mucosa could result in the probe 
 33
penetrating into the submucosa, which results in sampling from two layers 
collectively instead of the intended single layer. 
 
1.4.2   Microdialysis Probe Extraction Efficiency 
 Microdialysis sampling is carried out under non-equilibrium conditions since 
the perfusion fluid is continuously pumped through the probe.  Therefore, the probe 
recovery must be known in order to use microdialysis sampling as a quantitative 
sampling tool [67,76].  The general equation to determine microdialysis probe 
extraction efficiency (EE) by the ratio of concentration (C) of analyte in the dialysate 
and the sample is as follows [84]: 
 
             
sampleperfusate
dialysateperfusate
 - CC
 -CC EE =      (7) 
 
In vivo, the Csample cannot be determined directly, so the use of microdialysis 
sampling as a quantitative tool relies on the determination of the EE.  A number of 
literature methods have been used previously to calculate the EE of the individual 
probe.  These methods are discussed in the following sections. 
1.4.2.1   In Vitro Methods 
 Methods to determine the probe EE have been carried out through in vitro 
methods [75].  However, if the probe is to be implanted in vivo, the EE determined in 
vitro is not the same as it would be in vivo.  The environment around the probe in the 
in vitro study is in a more hydrodynamic environment. A probe implanted in a tissue 
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has different diffusion properties resulting in a decrease in EE in vivo. Therefore, 
probes that are used for in vivo quantitative studies must be calibrated as such. 
1.4.2.2   No-Net-Flux 
 The no-net-flux method is used to look at transport across the probe 
membrane as a function of varying the analyte concentration in the perfusate [85,86].  
The analyte is added to the perfusate at different concentrations.  When the 
concentration of analyte is greater in the perfusate than the surrounding environment, 
the analyte will be delivered from the probe.  When the analyte concentration in the 
surrounding environment is greater than the concentration in the perfusate, the analyte 
will diffuse into the probe.  The transport of the analyte into and out of the probe is 
reflected in the resulting dialysate concentrations.  When the concentration in the 
perfusate and the surrounding environment are equal, there will be no net flux of 
analyte.  A plot of the change in the dialysate concentration versus the initial 
perfusate concentration is made, where the slope is the EE and the x-axis is the 
determined concentration in the surrounding extracellular fluid [85,86].  The main 
disadvantage is that this method of calibration is very time consuming, taking over 8 
hours to have a sufficient number of different concentrations to plot against [85].  
1.4.2.3   Retrodialysis 
 The determination of microdialysis probe EE by adding a marker to the 
perfusate solution and monitoring any changes in that marker over time is called 
retrodialysis [61,64,65]. The chosen marker must be chemically similar and have 
almost identical transport through the probe and diffusion through the studied site as 
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the analyte.  However, the marker must be analytically distinguishable from the 
analyte to monitor both compounds.  Finding a compound with analogous properties 
of transport through the probe makes retrodialysis a difficult method for probe 
calibration.  Radiolabeled forms of analytes can been used as markers, but labeling 
the compound and having the analytical tools to measure the labeled compound can 
be expensive [61,87]. 
1.4.2.4   Calibration by Delivery of Analyte 
 A modification to retrodialysis to determine the EE of the microdialysis probe 
is by delivery of actual analyte through the probe [60,66,85].  A low concentration of 
the analyte is perfused through the probe.  Samples are analyzed once a steady state 
of delivery is achieved, as monitored through the dialysate concentration.  The 
extraction efficiency by delivery (EEd) is derived from Equation 7.  For delivery 
studies, there is no initial concentration of analyte in the sample so the equation 
becomes 
         
dialysate
dialysateperfusate
d
C
CCEE −=       (8) 
 
For recovery studies, there is no analyte in the perfusate so the EE, derived from 
Equation 7, becomes: 
 
                                                      
sample
dialysate
r
C
CEE =                                                         (9) 
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Transport across the probe should be independent of direction, therefore, equal for 
both the delivery and recovery [75].  By this assumption, the EEd value equals the 
EEr.  Therefore, the analyte concentration in the sample or tissue of interest (Csample), 
can be calculated by determining the concentration in the dialysate (Cdialysate) and 
substituting the EEd for EEr in Equation 9. 
 
1.4.3   Advantages to Microdialysis Sampling 
 Microdialysis sampling as a site-specific technique is an improvement over 
traditional sampling techniques.  Because of the MWCO of the membrane, only small 
molecules readily diffuse through the probe.  Proteins and large molecules are 
excluded from the dialysate, making sample pretreatment typically unnecessary for 
analysis.  The perfusion fluid is continuously pumped through the probe resulting in 
no net fluid loss from the system under study, which maintains equilibrium in the 
system during sampling.  Multiple samples are taken from the same probe, which 
reduces variability in the study and for in vivo studies also reduces the number of 
animals used for the study.  In addition, the animal can serve as its own control, 
further reducing variability [77]. 
 
1.4.4   Disadvantages of Microdialysis Sampling 
 Microdialysis sampling is not an all-inclusive sampling technique.  The 
probes must be continuously infused with the perfusion fluid.  The most common way 
to deliver the perfusion fluid is by a syringe pump, which requires the animal to be 
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tethered so the probe inlets and outlets do not get tangled as the animal moves.  
However, a solution to this problem is the commonly used BASi Raturn™ system 
(West Lafayette, IN) where the animal can move freely without tangling and breaking 
the probe tubing [77].  Another disadvantage is that microdialysis probes are fragile 
by nature, especially linear, vascular and shunt probes.  Care must be taken to not 
damage the membrane or the tubing for the probe inlet and outlet.  A further 
drawback to microdialysis is that it is a time consuming technique since probes have 
to be calibrated in addition to the actual sampling experiment when microdialysis is 
used for quantitative sampling.  Moreover, probe implantation procedures are difficult 
in areas of heterogeneous tissues, such as the GI tract and the skin, where 
implantation of the probe within a certain region of the tissue is more difficult in 
comparison to homogenous tissues, such as the liver.  Probe implantation techniques 
will be discussed in-depth in Chapter Two.  Nonetheless, microdialysis sampling 
offers an unparalleled opportunity for site-specific tissue sampling. 
 
1.4.5   Microdialysis Sample Analysis 
 The most common analytical techniques to analyze dialysate samples are by 
liquid chromatography (LC) or capillary electrophoresis (CE) with an appropriate 
detection scheme [61-65,76,81].  Dialysate samples contain high salts from the 
perfusion fluid, which can present a challenge for detection with some analytical 
systems such as mass spectrometry (MS) where high salt samples can impede the 
ionization source and create high background noise [76].  Methods to improve 
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detection limits of LC-MS, such as the use of capillary LC or online desalting 
techniques (e.g. desalting columns or solid phase extraction (SPE)) have been 
developed [88-92].   Microdialysis sampling itself is continuous, but fractions are 
collected and analyzed, which is a limiting factor in the temporal resolution achieved.  
The flow rate of the perfusion fluid through the probe can be increased, but results in 
less recovery from the probe and dilution of the analyte below detectable limits.  
Decreasing the flow rate through the probe, increases recovery through the probe, but 
results in smaller sample volumes.  On-line capillary electrophoretic and microchip 
separation based methods have been developed to analyze small sample volumes and 
have been used for microdialysis sampling experiments with rapid sampling intervals 
[81,93,94]. 
 
1.5   Scope of This Research  
 
 This research focuses on extending the use of microdialysis sampling with the 
development of a multiple probe approach to simultaneously implant probes in 
different layers of the rat stomach.   Initially, methods for a four-probe design in the 
stomach lumen, mucosa, submucosa and in blood were developed in the normal rat 
stomach.  This design was further extended to developing a multiple-probe approach 
of implanting probes to compare both normal and ulcerated tissue of the same rat 
stomach.  The significance of this multiple probe approach was determined by 
studying drug absorption through both the normal and ulcerated stomach.   
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 The hypothesis is that since the stomach tissue is heterogeneous, different 
analyte concentrations would be expected between the tissue layers.  A difference 
would also be expected when comparing tissue types (i.e. healthy versus diseased 
tissue). Probe implantation methods developed within the different layers or into 
different tissue types would improve sampling methods in the stomach.  The 
significance of sampling by this approach was determined by monitoring drug 
concentration in each of the studied sites after three test compounds with differing 
degrees of absorption in the rat stomach were dosed.  The ultimate aim of this 
research was to extend this technique to implant multiple probes within the intestines.  
Multiple probes implanted in several points throughout the GI tract can be used as a 
technique to determine the location and extent of absorption in the GI tract drug 
development studies.  Currently, this cannot fully be assessed by the techniques 
mentioned in Section 1.3.  The stomach is the first possible segment of the GI tract 
for significant absorption to occur, so methods of probe implantation were developed 
in the stomach for this research. 
 Development of the multiple-probe design of microdialysis sampling in both 
the normal and ulcerated rat stomach is discussed in Chapter Two.  Results of using 
this design to study drug absorption in both the normal and ulcerated stomach are 
presented in Chapter Three.  The summary and future goals for this research are 
described in Chapter Four. 
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CHAPTER TWO 
 
Implantation of Multiple Microdialysis Probes in the Rat Stomach 
 
 
2.1   Introduction 
 
 Microdialysis sampling is a well-established technique to monitor analyte 
concentrations in several tissues in vivo.  An in-depth discussion of this sampling 
technique was presented in Section 1.4.  Among the various uses of this technique, 
microdialysis probes have been implanted in the stomach submucosa to monitor 
endogenous analytes.  Originally, Bunnett et al. implanted a bundle of 20 dialysis 
fibers in the submucosa of the dog stomach [1].  In order to implant the fibers in the 
submucosa, a long incision was made on the muscularis externa and the bundle was 
placed into this incision.  The wound was then sutured closed over the bundle to 
encapsulate the fibers in the submucosal space.  In other studies, this technique was 
extended to rabbits and rats by reducing the number of dialysis fibers in the bundle to 
10 and 6 fibers, respectively [2,3].  However, this method of a long incision and 
suturing on the stomach was determined to be too surgically invasive.  Surgical 
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procedures that minimize perturbation to the system under study are an important 
aspect of in vivo sampling.  In 1997, Iversen et al. placed a rigid, concentric cannula-
style microdialysis probe, discussed in Section 1.4.1.1, into the rabbit stomach 
submucosa [4].  The probe was implanted by puncturing the serosal surface with a 
needle then the probe was inserted tangentially into the antrum of the stomach.  This 
method was successful for probe implantation in the submucosa; however, because 
the mucosa is a more dense tissue layer, implantation into the mucosa by this 
procedure would most likely damage the probe membrane, which is inserted first into 
the tissue.  Furthermore, the use of a rigid probe in the stomach could cause tissue 
tearing during peristalsis or general animal movement during in vivo sampling.  A 
more flexible probe would be more suitable for sampling in the stomach.  Kitano et 
al. developed methods of implanting a flexible microdialysis probe in the rat stomach 
submucosa [5].  A 22-gauge needle was used as a guide cannula to tunnel along the 
submucosa.  The use of a flexible probe minimized tissue tearing due to animal 
movement; however, the use of such a big guide needle during implantation can cause 
damage to the tissue upon insertion of the guide.  This method of implanting probes 
in the stomach submucosa has been used for several other studies to monitor 
endogenous compounds such as histamine release from enterochromaffin-like (ECL) 
cells [5-9].  ECL cells; however, are located in the mucosa layer while the probes 
were implanted in the submucosa layer.  Kitano et al. stated that sampling in the 
submucosa may not accurately represent the amount of histamine released since 
degradation can occur as histamine diffuses from the mucosa to the submucosa and 
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subsequently to the microdialysis probe [5].  The addition of sampling in the mucosa 
would enhance previous studies of microdialysis sampling in the stomach.  
 Furthermore, the ability to implant microdialysis probes simultaneously in 
both the mucosa and submucosa would significantly improve sampling from the 
stomach tissue.  Even though the possibility of implanting several microdialysis 
probes simultaneously into one animal exists, for most studies, sampling is performed 
by a single or dual probe approach where a probe is implanted in the target tissue and, 
in some cases, also in the blood for comparison [10-13].  Microdialysis sampling 
from a single probe in a well-perfused, homogeneous tissue, such as the liver, results 
in a good representation of concentrations from the whole tissue.  However, in tissues 
that consist of different layers (i.e. heterogeneous tissues) microdialysis sampling by 
a multiple probe approach in each layer is a more accurate approach to monitoring 
tissue concentrations.  In a study by Mathy et al., for example, microdialysis probes 
were implanted simultaneously in the skin dermal and subcutaneous layers to monitor 
skin concentrations from iontophoretically applied flurbiprofen [11].  This study 
reported a concentration gradient observed in the tissue with Cmax values of 8.7 
µg/mL and 0.5 µg/mL flurbiprofen in the dermis and subcutaneous layers, 
respectively.  The use of a dual-probe approach in the skin was useful to assess the 
differences in concentrations of these two tissue layers.  Like the skin, the stomach is 
a heterogeneous tissue where a multiple probe approach to microdialysis sampling to 
monitor both the mucosa and submucosa layers would enhance the current uses of 
microdialysis sampling in the stomach [6,8,9]. 
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2.2   Specific Aims of This Research 
 
 The purpose of this research was to develop a multiple probe microdialysis 
sampling design of implanting microdialysis probes in different regions of the 
stomach.  A multiple probe approach to monitor several layers in the same stomach 
has not been reported and would be an improvement to the current uses of gastric 
microdialysis sampling.  In the normal, healthy rat stomach, a four-probe 
microdialysis sampling design that targets simultaneous monitoring in the stomach 
lumen, mucosa, submucosa and in the blood was developed.  For further application, 
a multiple probe approach was also utilized to implant probes simultaneously in both 
normal and ulcerated stomach tissue to compare healthy and diseased tissue. In this 
model, probes were implanted in the stomach lumen, submucosa of both normal and 
ulcerated tissue and in the blood.  The significance of this multiple probe approach 
was tested by monitoring drug absorption in both normal and in ulcerated stomach 
models.  The results from drug absorption studies will be discussed in Chapter Three.   
 The studies presented in this chapter pertain to the design and implantation of 
microdialysis probes in both the normal and ulcerated tissue.  Particularly, methods of 
probe implantation in the mucosa and ulcer were developed since implantation in 
these tissues has not previously reported in the literature.  In addition, determination 
of an appropriate ulcer model, tissue response to probe implantation and fasting 
methods are discussed.  
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2.3   Chemicals and Reagents 
 
 Ringer’s solution consisted of 145 mM NaCl, 2.8 mM KCl, 1.2 mM CaCl2 
and 1.2 mM MgCl2.  Artificial gastric solution (pH 2.5-3.0) consisted of 87.4 mM 
NaCl, 4.0 mM KCl, 0.8 mM MgSO4, 2.1 mM Na2SO4 and 19.3 mM mannitol.  All 
chemicals for Ringer’s and artificial gastric solution were purchased from Sigma (St. 
Louis, MO, USA) or from Fisher Scientific (Fair Lawn, NJ, USA).  Water for 
Ringer’s solution and artificial gastric solution preparation was processed through a 
Labconco WaterPro Plus water purification system (18 MΩ/cm) (Kansas City, MO, 
USA) and filtered through a 47 mm, 0.22 µm nylon filter prior to use.  Isoflurane was 
purchased from Fort Dodge Animal Health (Fort Dodge, IA, USA).  Xylazine was 
purchased from Lloyd Laboratories (Shenandoah, IA, USA).  Acepromazine was 
purchased from Boehringer Ingelheim Vetmedica, Inc. (St. Joseph, MO, USA).  
VetBond tissue glue was purchased from 3M (St. Paul, MN, USA).  Lactated 
Ringer’s and 5% dextrose in lactated Ringer’s were purchased from B Braun Medical 
Inc. (Irvine, CA, USA). 
 
2.4   Microdialysis Probe Construction 
 
 Due to the flexibility of the linear microdialysis probe, this probe geometry 
was used for probe implantation in the stomach lumen, mucosa and submucosa.  The 
flexible cannula style probe has been used for microdialysis sampling in the blood 
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and therefore, was used for implantation in the jugular vein for these studies.  The 
procedures for probe construction for both the linear and flexible cannula probe 
(vascular probe) are discussed in the following sections. 
 
2.4.1   Linear Probe 
 Linear microdialysis probes were fabricated in-house with modification from 
a previously described technique [14].  These probes were designed for implantation 
in the stomach lumen, mucosa and submucosa of normal and ulcerated tissue.  This 
probe was designed in a successive fashion so the probe inlet connected to the 
membrane and the membrane further connected to the outlet.  The components for 
probe fabrication were polyacrylonitrile (PAN) dialysis fiber (molecular weight cut-
off (MWCO) 40 kDa, 350 µm outer diameter (o.d.) and 250 µm inner diameter (i.d.)) 
(Hospal Industrie, Meyzleu, France), polyimide tubing (223 µm o.d., 175 µm i.d.) 
(Microlumen, Inc., Tampa, FL, USA) and tygon microbore tubing (1520 µm o.d., 508 
µm i.d.) (Norton Performance Plastics, Akron, OH, USA).  Figure 2.1 represents 
linear probe construction in a stepwise manner.  A six-inch piece of polyimide tubing 
was cut for the probe inlet and a 10-15 mm piece of PAN dialysis fiber was used for 
the probe membrane.  As shown in Figures 2.1a and 2.1b, the inlet tubing and the 
membrane were joined by sliding the inlet tubing into the lumen of the membrane (≥ 
2.5 mm into the membrane).  A thin layer of UV glue (Ultraviolet Exposure Systems, 
Sunnyvale, CA, USA) coated the tubing/membrane junction.  A short piece of fused 
silica capillary tubing (363 µm o.d., 50 µm i.d.) (Polymicro Technologies, Phoenix, 
 
 
(a)  
 
 
 
 
 
 
 PAN Membrane Polyimide 
Inlet Tubing  
 
 
 
 
 
 
Figure 2.1.  Linear microdialysis probe construction. (a) Inlet tubing and 
membrane, (b) inlet and membrane joined and (c) microscopic view of 
inlet tubing and membrane glued by UV curing (20x magnification). 
Figures 2.1d-f on the following page. 
(b) 
(c) 
UV Glue 
Inlet/Membrane 
Junction 
1 mm 
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(d)  
 
 
 
 
 
 
Combined Inlet and  Polyimide Outlet  Membrane
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 continued.  Linear microdialysis probe construction. (d) Probe 
from Figure 2.1b and outlet tubing, (e) completed probe and (f) connection of 
tygon adaptor to probe inlet.  Figures 2.1a-c are on the previous page. 
(f) 
(e) 
Effective Membrane Length 
UV Glue 
Tygon Adaptor Inlet 
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AZ, USA) was used to apply the glue to the probe.  The UV glue was set by curing 
with an ELC-450 UV light system (Electrolite Corporation, Bethel, CT, USA).  
Figure 2.1c is a view of the applied glue on the junction.  A twelve-inch piece of 
polyimide tubing was used for the probe outlet.  The probe outlet was joined to the 
membrane by sliding the outlet tubing into the lumen of the membrane until the 
effective membrane length of 5 mm was reached, shown in Figures 2.1d and 2.1e.  
The outlet tubing and membrane were connected at the tubing/membrane junction by 
UV curing as described above and shown in Figure 2.1c.  To introduce perfusion fluid 
through the probe, an adaptor was connected to the probe inlet that could connect to a 
syringe of perfusion fluid.  A small piece of tygon microbore tubing was slid over a 
small section of the probe inlet and UV glue was used to connect the two pieces, as 
shown in Figure 2.1f.  All linear probes were stored in a sealed plastic bag and used 
within one week of construction. 
 
2.4.2   Vascular Probe 
 Vascular microdialysis probes were fabricated in-house for implantation in the 
jugular vein with modification from a previously reported procedure [15].  The probe 
was a flexible side-by-side cannula-style probe.  In this type of probe, perfusion fluid 
is introduced to the membrane through the probe inlet.  The perfusion flows through 
the membrane and into an outlet chamber where the probe outlet carries the perfusion 
fluid out of the probe.  The components for probe fabrication were PAN dialysis fiber 
(MWCO 40 kDa, 350 µm o.d., 250 µm i.d.) (Hospal Industrie, Meyzleu, France), 
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polyimide tubing (163 µm o.d., 122 µm i.d.) (Microlumen, Inc., Tampa, FL, USA), 
MicroRenathane® MRE-033 tubing (838 µm o.d.; 356 µm i.d.) (Braintree Scientific, 
Braintree, MA, USA), polyethylene tubing (PE-50) (965 µm o.d., 580 µm i.d.) 
(Fisher Scientific, Fair Lawn, NJ, USA) and tygon microbore tubing (1520 µm o.d., 
508 µm i.d.) (Norton Performance Plastics, Akron, OH, USA).  Figure 2.2 represents 
vascular probe construction in a stepwise manner.  One end of a 15 mm piece of PAN 
membrane was glued closed by UV curing with an ELC-450 UV light system and UV 
glue.  The glue was dabbed at the end of the membrane using a small piece of fused 
silica capillary tubing.  Figure 2.2a shows the membrane before and after application 
of UV glue.  The excessive amount of glue on the tip of the UV glued membrane was 
cut away with a straight edge blade.  A six-inch piece of polyimide tubing was used 
for the probe inlet.  The inlet was slid into the lumen of the membrane piece leaving a 
small gap between the tubing and the closed side of the membrane, as illustrated in 
Figures 2.2b and 2.2c.  A 10 mm piece of MRE-033 tubing was used as the outlet 
chamber.  The outlet chamber was slid over the probe inlet and was connected to the 
membrane piece, exposing only the effective membrane length (10 mm).  This 
junction was joined by a small amount of UV glue, as shown in Figure 2.2d.  A 
twelve-inch piece of polyimide tubing was used for the probe outlet and was inserted 
into the MRE-033 outlet chamber.  As shown in Figure 2.2e, a small gap was made 
between the outlet tubing and the membrane in the outlet chamber.  UV glue was 
used to close the outlet chamber, as shown in Figure 2.2f.  To add extra support to the 
probe, a 20 mm piece of PE-50 was slid over the inlet and outlet tubing and was 
 
 
(a)  
 
 
 
 
 
 
 
PAN Membrane  UV Glued Tip 
 
 
 
Figure 2.2.  Vascular microdialysis probe construction. (a) Membrane glued 
closed at one end (20x magnification), (b) inlet tubing and membrane and (c) 
inlet slid into membrane lumen, portion of figure 20x magnification.  Figures 
2.2d-h are on the following pages. 
(b) 
Polyimide Inlet 
Membrane 
(c) 
 Glued Tip Polyimide 
Membrane 
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Figure 2.2 continued.  Vascular microdialysis probe construction.  (d) 
Connection of membrane to the outlet chamber, (e) insertion of probe outlet 
tubing into the outlet chamber and (f) closing off of the outlet chamber with 
UV glue.  Figure 2.2f and portions of 2.2d and 2.2e at 20x magnification.  
Figures 2.2a-c are on the previous page and 2.2g-h are on the following page.  
Outlet 
Membrane 
Outlet Chamber 
Outlet 
UV Glue 
(e) 
(f) 
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Figure 2.2 continued.  Vascular microdialysis probe construction.  (g) 
Connection of PE-50 support tubing to the outlet chamber and (h) bead of 
UV glue to connect the PE-50 support to the outlet chamber.  Figures 2.2 a-f 
are on the previous pages. 
(h) 
Bead of UV Glue 
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connected to the outlet chamber as shown in Figure 2.2g.  A bead of UV glue was 
added at the outlet chamber/PE-50 junction to join the pieces and also to create a 
stopping point for the probe when inserted into the jugular vein.  A short tygon 
microbore tubing piece was used as an adaptor to connect the probe inlet to a syringe 
containing perfusion fluid.  As previously described above, a small piece of tygon 
microbore tubing was slid over a small section of the probe inlet and UV glue was 
used to connect the two pieces, shown in Figure 2.1f.  All vascular probes were stored 
in a sealed plastic bag and used within one week of construction. 
 
2.5   Fasting Procedures 
 
 Because food and stomach particulates would interfere with microdialysis 
sampling in the stomach lumen, the rats were fasted prior to experimentation.  From 
literature, a common method of fasting is to simply remove food from the animal 
cage for an extended period of time (24-48 hours) prior to experimentation while 
giving water ad libitum [7-9].  When this fasting procedure was performed, removal 
of food alone was found to not prevent coprophagy.  Therefore, particulates including 
feces, cage bedding and hair, were found in the stomach.  Several reports have 
utilized mesh wire bottom cages (metabolism cages) in addition to removal of food 
for 24-48 hours for fasting methods [6,16,17].  When using a metabolism cage for 
fasting, particulates and hair were still present in the stomach, indicating this fasting 
method was not successful in the prevention of coprophagy or self-grooming.  In 
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addition to the physical appearance of particulates in the stomach, basal lumen 
dialysate samples resulted in several large unidentified peaks chromatographically as 
shown in Figure 2.3a. 
 Elizabethan collars (or cones) have been placed around the neck of animals 
for the prevention of self-grooming after surgery or topical application of 
pharmaceuticals [18-21].  Incorporation of an Elizabethan collar was added to the 
fasting procedure to prevent coprophagy and self-grooming.  With the addition of an 
Elizabethan collar to fasting procedures in a metabolism cage, the previously seen 
interfering peaks in the lumen dialysate chromatograms were absent, as shown in 
Figure 2.3b.  Furthermore, a complete fasting with no particulate matter or hair 
present in the stomach lumen was observed.  Therefore, the optimized fasting 
procedure was to place the rat in a metabolism cage with a rodent Elizabethan collar 
affixed around their neck for 15-20 hours.   
 
2.6   Designs for Multiple Probe Microdialysis Sampling in the Stomach 
 
2.6.1   Probe Implantation in Normal Rat Stomach 
 To simultaneously monitor different stomach tissue layers, multiple 
microdialysis probes were implanted in the stomach lumen, mucosa, submucosa and 
also in the blood of the same rat.  Female Sprague Dawley rats (225-300 grams) 
(Charles Rivers Laboratories, Inc., Wilmington, MA, USA) were initially housed 
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Figure 2.3.  HPLC- UV chromatograms of luminal dialysate after fasting by 
(a) removal of food for 24 hours in a metabolism cage and (b) removal of 
food for 15 hours in a metabolism cage with an Elizabethan collar around 
the neck.  Conditions:  Phenomenex Synergi Polar-RP C18 column (150 x 
2.0 mm); 50 mM sodium phosphate (pH = 2.5) with 25% acetonitrile at 0.35 
mL/min; 10 µL injected into a 25 µL PEEK loop; detection at 228 nm. 
with access to food and water in temperature and humidity controlled rooms on a 12- 
hour light/dark cycle.   
All experiments were in accordance with the Principles of Laboratory Animal 
Care (NIH Publication no. 85-23, revised 1985) and approved by the University of 
Kansas Institutional Animal Care and Use Committee (IACUC).   
2.6.1.1   Linear Probe Implantation 
2.6.1.1.1   Determination of Implantation Method 
 Because of the flexibility of the linear microdialysis probe, some type of 
introducer is typically used for implantation of microdialysis probe to protect it from 
damage during implantation.  As described in Section 1.4.1.2, many studies reported 
implantation of linear probes in peripheral tissues with the use of a guide cannula.  
The guide was initially inserted into the tissue and the probe was inserted into the 
inside of the needle.  Once the guide was removed, the probe remained implanted in 
the tissue.  In addition, this same method was used in previous reports to implant 
probes in the stomach submucosa [7-9].  To protect the probe from damage during 
implantation, a guide needle was chosen for this research.  The guide needle used for 
this research needed to be rigid enough to puncture into the tissue, small enough to 
tunnel into one tissue layer separately and also needed to have an inner diameter large 
enough to slide the probe into the needle lumen once the guide was implanted.  
Initially, the thickness of the stomach layers needed to be determined to choose the 
appropriate diameter guide needle.   
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 To measure the stomach tissue layer thickness, stomach tissue with no prior 
perturbation to the tissue was harvested and placed in approximately 20 mL of 10% 
neutral buffered formalin for at least 24 hours.  The specimens were taken to the 
pathology lab at Lawrence Memorial Hospital (Lawrence, KS, USA) where the tissue 
was embedded into paraffin wax blocks and tissue slices were mounted onto 
microscope slides.  For tissue visualization, the slides were stained with hematoxylin 
and eosin (H and E) dyes.  Under a light microscope, the stomach layer thickness was 
measured.  Figure 2.4 shows a microscopic view of a representative histology slide of 
the stomach tissue and Table 2.1 shows the determined thickness of the layers of the 
female Sprague-Dawley rat stomach. 
 
Rat Stomach Tissue 
Layer 
Thickness of Layer (mm) 
(n = 15) 
Mucosa 0.69 ± 0.28 
Submucosa 0.50 ± 0.42 
Muscularis Externa 0.21 ± 0.21 
Entire Stomach 1.40 ± 0.49 
 
Table 2.1.  Rat stomach layer thickness  
 
The results show that the entire stomach tissue was nearly 1.5 mm thick with 
approximately 50% of the tissue as mucosa and 35% of the tissue as submucosa.  
 The outer diameter of the linear microdialysis probes used for this research 
was 350 µm.  Therefore, a proper size guide needle to maintain a 350 μm probe 
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 Mucosa 
Submucosa 
0.25 mm 
Figure 2.4.   Histology image of normal stomach tissue at 40x magnification. 
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correctly in the mucosa layer (690 µm) and in the submucosa (500 µm) was needed.  
A 25-gauge needle (500 µm o.d.; 260 µm i.d.; 1.5 inch length), was found to be of a 
suitable diameter to implant in both the mucosa and submucosa separately and to 
thread the polyimide of the probe inside the needle and was chosen for implantation 
of linear probes in the stomach. 
2.6.1.1.2   Stomach Ligation and Gavage Tube Insertion 
 The rats were fasted prior to probe implantation procedures to clear the 
stomach contents, as described above in Section 2.5.  After the fasting period, the rats 
were pre-anesthetized by isoflurane inhalation.  The rats were then given a 
subcutaneous injection of a ketamine (67.5 mg/kg), xylazine (3.4 mg/kg), 
acepromazine (0.67 mg/kg) mixture.  The rat’s body temperature was maintained 
throughout the surgery and experimentation at 37˚C by placing the rat on a heating 
pad (CMA 150 Temperature Controller, North Chelmsford, MA, USA).  Two 
milliliters of 2.5% dextrose in lactated Ringer’s was given subcutaneously as a means 
to replenish fluid to the rat while under anesthesia.  The hair on the abdomen and 
neck was shaved and excess hair was wiped away with 70% isopropyl alcohol.  
Anesthesia was monitored during the entire length of experimentation and 
intramuscular injections of 20-40 mg/kg ketamine were given as needed to maintain 
adequate anesthesia. 
 The stomach was exposed by a midline incision on the abdomen.  This 
incision was held open with a Bowman retractor (2.5 cm spread) (Fine Science Tools, 
Foster City, CA, USA).  To contain a constant volume of fluid in the stomach lumen, 
the stomach was ligated closed at the cardiac and pyloric sphincters.  Figure 2.5 
shows the ligation of the pyloric sphincter.  To ligate the pyloric sphincter, the 
stomach and duodenum junction was cleared of mesenteric tissue by gently rubbing 
the tissue away from the junction with a soaked cotton swab as shown in Figure 2.5a.   
Once the mesentery tissue was cleared, a 3-0 silk suture was threaded under the 
pyloric sphincter, as shown in Figure 2.5b.  Figure 2.5c shows the suture tied off at 
the pyloric sphincter to keep the stomach contents from passing to the duodenum.   
 Artificial gastric solution was injected into the stomach of the anesthetized rat 
by a gavage tube.  Figure 2.6 shows the insertion of the gavage tube and cardiac 
sphincter ligation.  The gavage tube was a 12-14 inch piece of MRE-80 tubing (2.0 
mm o.d., 1.0 mm i.d.) (Braintree Scientific, Braintree, MA, USA).  As shown in 
Figure 2.6a, the gavage tube was passed through the mouth, down the esophagus, past 
the cardiac sphincter and into the stomach lumen.  A 3-0 silk suture was used to ligate 
the cardiac sphincter to contain gastric contents in the stomach as well as hold the 
gavage tube in place during experimentation, as shown in Figures 2.6b and 2.6c.  The 
exposed end of the gavage tube was connected to a blunt 18-gauge hypodermic 
needle that was connected to a 5 mL plastic syringe.  The stomach was flushed 
several times with water and with artificial gastric solution until the solution in the 
stomach was clear.  All stomach solution was removed and 3 mL of fresh gastric 
solution was injected into the stomach via the gavage tube.  Figure 2.7 shows the 
fully ligated stomach with 3 mL of gastric solution injected into the stomach lumen.  
The procedures described up to this point were performed to prepare the stomach for 
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Esophagus 
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Figure 2.6.  Gavage tube insertion and cardiac sphincter 
ligation.  (a) Insertion of gavage tube through the mouth, (b) 
suture in place near the cardiac sphincter and (c) gavage tube 
ligated in place at the cardiac sphincter. 
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 Figure 2.7.  Stomach ligated at the cardiac and pyloric sphincters with 3 mL 
of artificial gastric solution injected into the stomach via gavage tube.   
Pyloric 
Ligation 
Cardiac 
Ligation 
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probe implantation.  Probe implantation techniques in the submucosa, mucosa, lumen 
and blood are described in the following sections. 
2.6.1.1.3   Submucosa Implantation 
 The submucosa and mucosa are of different tissue types, the submucosa is 
connective tissue and the mucosa, comprised mostly of lamina propria, is a more 
dense tissue relative to the submucosa [22].  The visual difference between a guide 
needle implanted in the submucosa and the mucosa was exploited to determine the 
correct layer of probe placement during the implantation procedure.  The submucosa 
is transparent on the serosal surface of the stomach.  Figure 2.8 shows the procedure 
of linear probe implantation in the submucosa.  The stomach can be classified into 
four regions:  the fundus, body, antrum and pylorus [22].  The body is the region of 
the stomach with the most surface area and also is the region where most absorption 
occurs in the stomach [22].  The body was therefore the target region of the stomach 
for probe implantation.  As shown in Figure 2.8a, the guide needle (25-gauge; 1.5 
inch length) punctured the stomach just below the serosal surface.  The needle was 
clearly visible underneath the serosal surface, indicating the guide was in the 
submucosa.  Care was taken to avoid tunneling the guide across major blood vessels 
that were visible on the serosal side.  As shown in Figure 2.8b, the guide was 
tunneled through the tissue enough to ensure that the probe membrane was 
completely embedded in the tissue once implanted.  The beveled end of the guide was 
used to exit the tissue.  The outlet of the linear probe was then threaded through the 
lumen of the needle, shown in Figure 2.8c.  The needle was removed from the tissue,  
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Guide Needle in 
the Submucosa 
(a) 
(b) 
Figure 2.8.  Microdialysis probe implantation in the stomach 
submucosa.  (a) Guide needle inserted into the stomach submucosa 
and (b) guide needle tunneled through the submucosa and then exiting 
the tissue.  Figures 2.7c-e on the following page. 
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Figure 2.8 continued.  Microdialysis probe implantation in the stomach 
submucosa.  (c)  Probe outlet threaded into the needle lumen, (d) Needle 
exiting tissue leaving probe in tissue and (e) probe implanted and 
secured in tissue.  Figures 2.8a-b are on the previous page. 
Probe threaded 
into needle
Needle 
removed 
from tissue 
Tissue glue on 
entrance and 
exit sites 
(c) 
(d) 
(e) 
 77
 78
leaving only the probe embedded in the tissue, as shown in Figure 2.7d.  The 
membrane of the probe was positioned until it was completely embedded in the 
tissue.  Tissue glue was used to close the probe entrance and exit sites as well as hold 
the probe in place in the submucosa.  Figure 2.8e shows the completed implantation 
of a linear probe in the stomach submucosa. 
2.6.1.1.4   Mucosa Implantation 
 Linear probe implantation into the stomach mucosa was performed in the 
same manner as the implantation of a linear probe in the submucosa.  Figure 2.9 
shows the procedure of implanting a probe in the mucosa next to a probe that was 
previously implanted in the submucosa.  As mentioned previously, the visual 
difference between a guide needle implanted in the mucosa relative to the submucosa 
was used to correctly implant probes in the appropriate layer.  Because the probes 
were implanted by hand and because of the sub-millimeter thickness of the mucosa 
and submucosa layers, this visual difference between the guide implanted in each 
layer was imperative in determining the location for probe implantation.  As 
illustrated in Figures 2.9a and 2.9b, when the guide needle (25-gauge, 1.5 inch length) 
entered and tunneled into the mucosa, the guide needle is not as visible on the serosal 
surface as previously seen when implanting in the submucosa (Figure 2.8a and 2.8b).  
After the guide needle was tunneled through the mucosa to an appropriate distance, 
the beveled end of the guide was used to exit the tissue.  The outlet of the linear probe 
was then threaded into the lumen of the guide needle, as shown in Figure 2.9c.  As 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a) 
Guide Entering 
Mucosa
(b) 
Guide Tunneled  
Submucosa Probe 
in Mucosa
Figure 2.9.  Microdialysis probe implantation in the stomach 
mucosa.  (a) Guide needle penetrating the mucosa layer and (b) 
guide needle tunneled through the mucosa layer.  Figures 2.9c-d 
are on the following page. 
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Figure 2.9 continued.  Microdialysis probe implantation in the stomach 
mucosa.  (c)  Guide needed tunneled through and exited from the 
mucosa and probe threaded in the guide and (d) probes implanted and 
secured in the mucosa and submucosa. Figures 2.9a-b are on the 
previous page. 
Submucosa 
Probe
Mucosa 
Probe
Guide in 
Mucosa
Probe in 
(c) 
Guide
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with the submucosal implantation, the guide needle was removed leaving the probe 
embedded in the mucosa.  The probe was appropriately positioned so the entire probe 
membrane was embedded in the tissue and the entrance and exit wounds were closed 
with tissue glue.  Figure 2.9d shows the successful implantation of linear probes 
implanted in both the mucosa and submucosa simultaneously in the rat stomach. 
2.6.1.1.5   Lumen Implantation 
 A guide needle (25-gauge; 1.5 inch length) was used to implant a linear probe 
into the stomach lumen, similar to the previously described techniques for 
implantation in both the submucosa and mucosa.  Figure 2.10 shows the guide needle 
in place in the lumen of a stomach with submucosa and mucosa probes previously 
implanted.  With the submucosa and mucosa probes previously implanted, limited 
surface area on the ventral side of the stomach body remained for probe implantation 
in the stomach lumen.  Therefore, the guide needle was inserted perpendicular to the 
direction of mucosa and submucosa probe implantation.  As previously shown in 
Table 2.1, the entire stomach thickness is approximately 1.5 mm, therefore 
penetration of the guide needle in the lumen was not as intricate as implantation 
directly into the stomach tissue layers.  Once the guide needle was positioned in the 
lumen, the probe was threaded in the needle and the needle was removed leaving only 
the probe in place in the lumen.  As previously used for the submucosa and mucosa 
probe, tissue glue was used to close the entrance and exit wounds and hold the lumen 
probe in place.   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Submucosa 
Probe Mucosa Probe 
Guide in Lumen 
Figure 2.10.  Microdialysis probe implantation in the stomach lumen. 
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 Lumen Probe 
Mucosa Probe 
Submucosa Probe 
Figure 2.11.  Linear microdialysis probes simultaneously implanted in the lumen, 
mucosa and submucosa of the rat stomach. 
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Figure 2.11 shows the simultaneous implantation of linear microdialysis probes 
simultaneously in the submucosa, mucosa and lumen of the normal rat stomach.  The 
incision on the abdomen was covered with wetted gauze and plastic wrap to keep the 
abdomen hydrated during experimentation.  In addition to the implantation of probes 
in the stomach, a vascular probe was implanted in the jugular vein of the same rat, 
resulting in four probe simultaneously implanted in one rat.  The procedures for probe 
implantation in the jugular vein are described in the next section. 
 2.6.1.2   Vascular Probe Implantation 
 A flexible cannula-style probe was implanted for systemic blood sampling in 
rats that had linear microdialysis probes implanted in the stomach.  The jugular vein 
was used for sampling because the vein was large enough to implant a probe into 
without tearing the vessel and also because the jugular vein is superficial and easily 
accessed.  Figure 2.12 demonstrates the procedure for isolation of the jugular vein.  
An incision was made on the skin of the neck and adipose tissue superficial to the 
vein was separated to expose the right jugular vein as shown in Figure 2.12a.  Extra 
tissue was cleaned from the vein and the vein was isolated onto a metal spatula, as 
shown in Figure 2.12b.  Figure 2.13 shows the procedure of vascular probe 
implantation in the jugular vein. After isolation of the vein, a small cut was on the 
vein with spring scissors (Fine Science Tools, Foster City, CA, USA) as shown in 
Figure 2.13a.  A dental pick, used as the probe guide, was inserted into the small cut 
made on the vessel, as shown in Figure 2.13b.  The guide was gently removed while 
 Figure 2.12.  Isolation of the jugular vein.  (a) Separated skin and adipose 
tissue to expose the jugular vein and (b) isolation of the jugular vein onto 
a metal spatula. 
(a) 
(b) 
Jugular vein 
Caudal 
Cranial 
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Figure 2.13.   Microdialysis probe implantation in the jugular vein.  (a) 
Making a small cut on vein, (b) insertion of a guide into the vein and (c) 
probe inserted into vessel.  Figures 2.13d-f are on the following page. 
Spring Scissors (a) Caudal 
Cranial 
(b) 
Guide Inserted 
in Vein 
(c) 
Probe Implanted 
in Vein 
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(d)  
 
 
 
 
 
 
Bead of Glue  
 
 
 
 
(e) 
Suture 
(f) 
Figure 2.13 continued.   Microdialysis probe implantation in the jugular 
vein.  (d) Probe inserted in the vein until the glue stop, (e) suture tied to hold 
the probe in place and (f) completed probe implantation in the jugular vein.  
Figures 2.13a-c are on the previous page. 
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simultaneously sliding the tip of the probe through the cut.  Once the guide was 
removed, the vascular probe remained in the vein with the probe membrane directed 
towards the heart as shown in Figure 2.13c.  The probe was inserted until the bead of 
glue of the probe reached the cut on the vessel as shown in Figure 2.13d.  This bead 
of glue was used as a stopper and also to prohibit sliding of the probe further in the 
vein.  The jugular vein was ligated with a 3-0 silk suture to further hold the probe in 
place as shown in Figures 2.13e and 2.13f.  The probe inlet and outlet were 
externalized through the incision and the incision was carefully closed with wound 
clips. 
2.6.1.3   Tissue Response to Probe Implantation 
Microdialysis probes have been shown to causes an inflammatory tissue 
response once implanted [14,16,23-25].  An inflammatory response has been shown 
to decrease microdialysis probe performance over time in long-term experiments (> 
24 hours) [14,24,25].  Studies by Ericsson et al. showed that when linear 
microdialysis probes were implanted into the stomach submucosa, inflammatory cells 
peaked around the third day after probe implantation and that a subtle edema and 
fibrotic layer were present throughout the entire experiment [16].  Because of the 
consistent small amount of edema and fibrotic tissue, it was determined that the 
amount of inflammatory cells present was the major factor in determining the tissue 
response to probe implantation in the submucosa.  Therefore, three days after probe 
implantation was sufficient for animal recovery from probe implantation for long-
term sampling in the submucosa [16].  Studies have reported that in the first 24 hours, 
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little or no inflammatory response occurs and that probe performance, monitored by 
delivery, was stable for 24 hours [14,24,25].  A “tissue equilibration” time of 
approximately 1 hour was found to be sufficient to allow for vasodilation to return to 
normal in order to begin sampling for short-term (< 24 hour) sampling [23]. 
 Because multiple microdialysis probes have not previously been implanted in 
the stomach, tissue response to probe implantation needed to be monitored for this 
research.  Probe implantation effects in the mucosa and submucosa were determined 
by histological examination as previously performed in the study by Ericsson et al. 
[16].  In addition to studying tissue response to probe implantation, the tissue slice 
results were used to verify the location of probe implantation in the mucosa and 
submucosa. 
 At the completion of experimentation, stomachs were harvested after rat 
euthanasia and tissue slices were mounted onto microscope slides as described in 
Section 2.6.1.1.1.  For tissue visualization, the slides were stained with H and E dyes.  
The results of several slides were discussed with a hospital pathologist. 
 Microdialysis sampling for this research was performed on anesthetized rats 
over a maximum of 12 hours.  The tissue response over time was studied at different 
time points throughout an experiment length.  Normal rat stomachs were harvested at 
certain time-points after microdialysis probes were implanted into the stomach tissue 
and were processed for histological examination.  Figure 2.14 shows the histology 
from stomachs harvested directly after, 2 hours after and 12 hours after implantation.  
The lack of inflammatory cells around the probe was an indication that a significant 
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(a) 
Probe 
Submucosa 
Mucosa 
Probe 
Mucosa 
Mucosa 
Probe 
(c) 
Submucosa 
(b) 
Figure 2.14.  Histology images of linear probe implantation (a) in 
the mucosa right after implantation, (b) in the submucosa 2 hours 
post implantation; right before probe calibration and (c) in the 
mucosa 12 hours after implantation.  Tissues stained with H and E 
dyes.  Figures 2.14a and 2.14c at 20x magnification, 2.14b at 40x 
magnification. 
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immune response did not occur over the course of the entire 12-hour experiment.  The 
results in Figure 2.14 illustrated that probes could be successfully implanted into the 
individual tissue layers in the stomach without penetration of the membrane into the 
other layers. 
2.6.1.4   Optimization of Linear Probe Membrane Length 
Several factors affect microdialysis probe recovery including  perfusion fluid 
flow rate, membrane and analyte properties, diffusion rates from and across the probe 
and probe geometry [26].  In conjunction with development of probe implantation 
techniques, the length of probe membrane (i.e. probe surface area) was optimized to 
maximize recovery through the probe. Generally, microdialysis probe recovery 
increases with longer membrane lengths, whereas shorter membrane lengths have less 
surface area and, therefore, less recovery at the same flow rate [27].  Decreasing the 
flow rate can help increase recovery and can be used to optimize recovery when 
shorter membrane lengths are used, but decreasing the flow will also increase the 
sampling rate since analytical systems are volume limited [26,28].  Although different 
membrane lengths have been used, a 10 mm membrane length for linear probes is 
frequently used since this length is small enough and exhibits good recoveries 
[5,8,11,29,30].  However, the probability of maintaining a shorter membrane in 500-
700 µm heterogeneous tissue layers is greater than with a longer membrane.  
Therefore, the effect on recovery due to decreased membrane lengths in vivo was 
studied.  After probe implantation in the stomach lumen, mucosa and submucosa by 
both 10 mm and 5 mm probes, extraction efficiencies by delivery of 10 µM salicylic 
 91
acid at 1 µL/min were determined.  Probe calibration by delivery was previously 
discussed in Section 1.4.2.4.  As illustrated in Table 2.2, with a 5 mm membrane 
length, recovery decreased by 24% relative to the 10 mm length.  Even though there 
was a loss in recovery with the 5 mm membrane, concentrations in the dialysate 
samples were still above the limits of detection (LOD), as will be discussed in 
Chapter Three.  Therefore, a 5 mm membrane length was used for this research to 
increase the probability of proper probe implantation within the separate stomach 
tissue layers. 
 
  Extraction Efficiencies  
Probe Location 10 mm Membrane 5 mm Membrane 
Lumen 77.5 ± 12.9   (n = 9) 56.6 ± 14.7   (n = 12) 
Mucosa 59.7 ± 3.8     (n = 2) 37.9 ± 13.1     (n = 6) 
Submucosa 64.1 ± 19.3   (n = 9) 33.8 ± 11.4   (n = 13) 
 
 
 
 
 Table 2.2.  Comparison of in vivo extraction efficiencies in the 
stomach layers from 10 mm and 5 mm linear microdialysis probes 
determined from the delivery of 10 µM salicylic acid at a 1 µL/min.  
 
2.6.2   Probe Implantation in the Ulcerated Rat Stomach 
 As a further application, the multiple probe approach was utilized to sample 
from different tissue types in the same stomach.  To simultaneously monitor healthy 
and diseased tissue, methods of multiple probe microdialysis sampling in the 
ulcerated stomach were developed to directly compare ulcerated to healthy tissue.  
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After chemical induction of an ulcer in the rat stomach, multiple probes were 
implanted in the stomach lumen, submucosa of normal and ulcerated tissue and also 
in the blood.   
The same type and weight range of female Sprague-Dawley rats used for 
implantation techniques in the normal stomach were used and housed the same for 
implantation in the ulcerated stomach. All experiments were in accordance with the 
Principles of Laboratory Animal Care (NIH Publication no. 85-23, revised 1985) and 
approved by the University of Kansas IACUC committee.  
2.6.2.1   Chemical Ulcer Induction 
Several models of chemically induced ulceration in the stomach have been 
reported [31-35].  Typically, administration of the ulcer-causing agent is via a gavage 
to the stomach lumen [31,34].  These methods have shown to be successful in 
creating multiple ulcerations within the stomach; however, the extent of ulceration 
was only visible from the stomach luminal side.  Endoscopic techniques or tissue 
excision was needed to visualize the ulcerated tissue [31-35].  In order to implant 
microdialysis probes into intact ulcerated tissue, the ulcerated tissue must be visible 
on the serosal side of the stomach.  A method originally developed by Takagi et al. of 
injecting 20% acetic acid (v/v) into the stomach submucosa reported ulcers visible on 
the serosal surface three days after acid injection [36].  This fit the necessary criterion 
for microdialysis probe implantation in a contained ulcer tissue on an intact stomach. 
For ulcer induction, all tools used were autoclaved with a Harvey SterileMax 
benchtop autoclave prior to use.  The rats were anesthetized using an isoflurane 
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vaporizer (VetEquip, Inc., Pleasanton, CA, USA).  A 95:5% O2:CO2 medical oxygen 
mix (Linweld Inc., Topeka, KS, USA) was delivered at 50 psi from the cylinder and 
metered by a flowmeter to 1-1.5 liters per minute to the vaporizer.  The oxygen was 
mixed with 2-3% isoflurane and delivered to a rodent nose cone which enabled the rat 
to inhale the anesthetic.  The excess isoflurane was scavenged with an activated 
charcoal filter.  A CMA/150 temperature controller and heating pad (North 
Chelmsford, MA, USA) was used to maintain the rat body temperature at 37°C.  The 
hair on the left side of the rat just below the ribcage was shaved and cleaned with 
alternate scrubs of betadine and 70% isopropyl alcohol.  This scrub procedure was 
repeated three times to sterilize the surgical area.  An incision was made just below 
the ribcage and the stomach was exposed.  A 27-gauge hypodermic needle was 
connected to a 1 mL syringe containing 20% acetic acid.  The needle was inserted 
into the submucosa of the body of the ventral side of the stomach and 50 μL of acid 
was injected into the submucosal space.  The muscle was sutured closed with 5-0 silk 
suture and the skin was closed with wound clips.  The rat was removed from 
anesthesia and given a subcutaneous injection of 0.1 mg/kg buprenorphine HCl as 
post-operative care.  The ulcer was allowed to form for the following three days. 
After the ulcer formation period, the ulcerated tissue, from the serosal surface, 
was circular with characteristic white tissue and blood engorgement at the ulcer base.  
Figure 2.15a demonstrates an ulcer from the serosal side of the stomach induced by 
acetic acid injection.  Histology slices from the ulcerated stomach were processed as 
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Submucosa 
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(a) 
Figure 2.15.  Gastric ulcer formed by injection of 20% acetic acid into the 
submucosa.  (a) Ulcer visibility from the serosal surface and (b) histology 
of ulcer.  Tissue stained with H and E dyes.  Image at 20x magnification. 
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described previously in Section 2.6.1.1.1.  Figure 2.15b illustrates the histology 
results from an ulcer induced by acetic acid injection.  This figure shows that this 
method was successful in creating a gastric ulcer with the complete degradation of the 
mucosal layer.  A subsequent increase in the submucosal layer thickness was also 
observed in the ulcerated tissue.   
A disadvantage to the acetic acid injection method of ulcer induction was that 
neighboring tissues (i.e. liver and adipose) would frequently strongly adhere to the 
ulcerated tissue.  Due to the fragile nature of the ulcerated tissue, the adhesion would 
cause the ulcerated tissue to perforate upon gentle manipulation.  The success rate of 
ulcers that did not perforate from adhering tissues was 65%.  Therefore, alternative 
methods of ulcer induction to decrease the frequency of perforation were explored.  
Initially, less severe ulcer causing agents were injected to determine if decreasing the 
severity of ulceration affected the amount of tissue adherence.  Figure 2.16 shows the 
histology results from stomach tissues three days after the injection of 50 μL of (a) 
10% acetic acid, (b) absolute ethanol and (c) 7 mM indomethacin in ethanol.  The 
histology results showed that all three chemicals injected resulted in only 
inflammation of the mucosa tissue.  A true gastric ulcer results in the complete 
erosion of the mucosal layer.  Therefore, these injected chemicals were not suitable as 
an ulcer model for this research.   
Another explored procedure to reduce tissue adherence was to coat the ulcer 
with sterile lubricant (E. Fougera & Co, Melville, NY, USA) directly after acid 
injection.  With a small amount of lubricant on the ulcer, the tissues easily separated 
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Figure 2.16.  Histology from the injection of (a) 10% acetic acid, (b) 
absolute ethanol and (c) 7 mM indomethacin in ethanol. 
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without perforating the ulcer with a success rate of non-perforated ulcers increasing to 
76%.  However, the resulting ulcers appeared smaller when viewed on the serosal 
surface.  This decrease in ulcer size was confirmed when comparing the ulcer index 
(UI) values, measured as the ulcer area (mm2) on the mucosal side, after the stomach 
tissue was harvested [37].  Table 2.3 shows the ulcer indices of both ulcers formed by 
the normal acetic acid injection method (no lubricant used) and the same method with 
lubricant application after injection. The traditional method resulted in ulcers that 
were twice the size of ulcers formed with lubricant used.  During the ulcer formation 
period, the lubricant may have absorbed into the stomach tissue, partially protecting 
the mucosa during ulcer formation.  Ultimately, the lubricant was used to control 
ulcer size (i.e. small ulcers (10-20 mm2) versus large ulcers (30-40 mm2)). 
 
 UI (mm2) 
Large Ulcer 37 ± 8 
Small Ulcer 17 ± 4 
 
 
 
 
Table 2.3.   Ulcer index values for large ulcers (no lubricant 
used) and small ulcers (lubricant used) (n = 9).  
 
2.6.2.2   Probe Implantation in Ulcerated Submucosa  
 As described in Section 2.6.2.1, an ulcer was formed in the stomach by acetic 
acid injection and allowed to form for the following three days.  The rats were fasted 
15-20 hours prior to probe implantation by the optimized fasting procedure described 
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in Section 2.5.  The same procedures described in Section 2.6.1.1.2 to prepare the 
stomach for probe implantation in the normal stomach were used in the ulcerated 
stomach. 
 Any tissue adhered to the ulcer was gently separated from the ulcer by 
rubbing the tissues with a wetted cotton swab.  As previously described for 
implantation of linear probes in the normal stomach, a guide needle (25-gauge; 1.5 
inch length) was used to implant a linear probe in the ulcerated tissue.  As shown in 
Figure 2.17, the guide needle penetrated the ulcerated tissue, was tunneled through 
the tissue and exited through the tissue using the beveled edge of the guide.  The 
probe was threaded through the inside of the guide and the guide alone was removed 
leaving the probe in place in the tissue.  The entrance and exit wounds were closed 
with tissue glue.  For implantation in the ulcer, tunneling the guide needle across the 
entire ulcer area was found to be more successful because of the fragile nature of the 
tissue.  Guide needles that exited through the middle of the ulcerated tissue caused the 
ulcer tissue to leak gastric solution through the serosal surface.  In addition to 
implanting a probe in the ulcerated submucosa, linear probes were implanted in the 
stomach lumen and submucosa of normal tissue as described in Sections 2.6.1.1.3 and 
2.6.1.1.5.  The incision on the abdomen was covered with wetted gauze and plastic 
wrap to keep the abdomen hydrated during experimentation.   A vascular probe was 
also implanted in the same rat as described in Section 2.6.1.2. 
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Figure 2.17.  Microdialysis probe implantation in the submucosa of ulcerated 
tissue.  (a) Guide needle penetrating the ulcer, (b) guide needle across the 
ulcerated tissue and (c) probe implanted in the ulcerated tissue. 
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 Figure 2.18.   Linear microdialysis probes simultaneously implanted in the 
lumen and submucosa of both ulcerated and normal tissue. 
Lumen Probe 
Ulcerated Submucosa 
Normal Submucosa 
Probe
Probe
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Figure 2.18 shows the completed implantation of linear microdialysis probes 
simultaneously in the lumen and submucosa of normal and ulcerated tissue in the 
ulcerated rat stomach. 
2.6.2.3   Verification of Probe Location 
 As describe previously, histology slides were processed from the tissue after 
experimentation to verify the location of the probe within the normal and ulcerated 
submucosa.  Harvested stomach tissue was mounted onto microscope slides as 
described previously in Section 2.6.1.1.1.  For tissue visualization, the slides were 
stained with H and E dyes. Results of several slides were discussed with a hospital 
pathologist.  Figure 2.19 shows a representative result of a linear probe implanted in 
the submucosa of ulcerated tissue.  From the slides, the complete erosion of the 
mucosa layer was observed as well as the successful probe implantation into the 
ulcerated submucosa. 
 
2.7   Conclusions 
 
 The research presented in this chapter focused on the development of 
techniques for implanting multiple microdialysis probes in rat stomach.  To compare 
different tissue layers, microdialysis probes were simultaneously implanted in the 
stomach lumen, mucosa, submucosa and in the blood.  It was determined that linear 
probes could successfully be implanted in the different stomach tissues with the use 
of a 25-gauge guide hypodermic needle.  Although a 24% decrease in the in vivo 
 Probe 
Ulcer 
Mucosa 
Figure 2.19.  Histology of a linear microdialysis probe implanted in the stomach 
submucosa of ulcerated tissue.  Tissue stained by H and E dyes.  Image at 20x 
magnification. 
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extraction efficiency was observed with a linear probe of a 5 mm effective membrane 
length relative to a 10 mm membrane at 1 µL/min, a 5 mm membrane length was still 
found to be suitable for this research.  This shorter membrane length increased 
theprobability of correct probe implantation without significantly sacrificing probe 
recovery.  Tissue response to probe implantation in the stomach mucosa and 
submucosa were studied.  No significant immune response was observed for up to 12 
hours post probe implantation in both the mucosa and submucosa. 
 As a further use for a multiple probe approach, a similar method was used to 
compare ulcerated and normal tissue in the same stomach.  An ulcerated stomach 
model was developed based on a literature method of chemical induction by injection 
of 20% acetic acid into the stomach submucosa.  A frequent problem with this 
method of ulcer induction was the adherence of neighboring tissues to the ulcer that 
could eventually perforate the ulcer.  To circumvent this adherence problem, sterile 
lubricant was used to coat the ulcer.  The lubricant effectively reduced tissue 
adherence, but also reduced the ulcer size.  This resulted in the ability of controlling 
ulcer size (large versus small) for studies as a function of ulcer size.  Multiple 
microdialysis probes were successfully implanted in the stomach lumen and 
submucosa of both ulcerated and normal tissue in the same rat.  A vascular probe was 
also implanted in the jugular vein resulting in a four-probe design in the ulcerated 
stomach model. 
 Finally, procedures to fast the rat prior to experimentation were developed 
since the frequently used method of removal of food did not result in a truly fasted rat 
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and caused the appearance of large, unidentified peaks in lumen basal dialysate.  
Fasting procedures were optimized by placing the rat in a metabolism cage with an 
Elizabethan collar affixed around their neck for 15-20 hours prior to experimentation. 
 Overall, the research discussed in the present chapter presented successful 
methods of multiple probe implantation techniques in both normal and ulcerated rat 
stomach.  To test the significance of sampling with this multiple probe approach, 
comparisons of drug concentrations determined at each study site from oral drug 
absorption studies were made.  The results from monitoring drug absorption in the 
normal stomach model as well as the large and small ulcer model will be presented in 
the next chapter. 
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CHAPTER THREE 
 
Monitoring Drug Absorption in the Stomach by Multiple Probe 
 Microdialysis Sampling 
 
 
3.1   Introduction 
 
 As described in Chapter Two, microdialysis probes were successfully 
implanted simultaneously into the different tissue layers of the stomach, namely the 
mucosa and submucosa layers.  A multiple probe microdialysis sampling approach 
will improve upon current uses of gastric microdialysis sampling, which are 
performed with a single probe in the submucosa layer.  In addition, multiple probes 
were implanted simultaneously in normal and diseased tissue of an ulcerated stomach 
model.  By this approach, a direct comparison of normal and ulcerated tissue of the 
same stomach was achieved. 
 Although multiple probes were implanted in this design, the significance of 
sampling by a multiple probe approach needed to be determined.  This was achieved 
by monitoring compounds with known absorption characteristics through the stomach 
after oral administration.  Schanker et al. originally studied the absorption of different 
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classes of compounds through the rat stomach by in situ closed loop methods that 
were described in Section 1.3.2.2 [1].  Based on this previous study, test compounds 
of differing degrees of passive absorption in the rat stomach were used to compare the 
extent of absorption determined from microdialysis sampling to their predicted 
absorption rates.  In addition, comparison of the test compound concentrations 
determined in each studied site by this microdialysis sampling design was used to 
assess the significance of this multiple probe approach. 
 
3.2   Specific Aims of this Research 
  
 The specific goals of this research were to use the previously described 
multiple probe design of microdialysis sampling in both normal and ulcerated 
stomach to monitor drug absorption after an oral dose was given to anesthetized rats.  
Three previously characterized test compounds with different degrees of absorption in 
the rat stomach were dosed by oral gavage to the ligated stomach.  The test 
compounds salicylic acid (SA), caffeine and metoprolol were chosen to represent 
high, moderate and low absorption in the rat stomach, respectively.  A summary of 
the chosen test compounds showing the structures, pKa values, log D (pH 2-3) values 
and the reported absorption rates of each compound in the rat stomach is presented in 
Table 3.1 [1-4].  Analysis of concentration-time curves and pharmacokinetics 
modeling for each test compound and each probe location will be presented in this 
chapter to assess the efficacy of this microdialysis sampling method in the stomach.
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3.3   Materials and Methods 
 
3.3.1   Chemicals and Reagents 
 Caffeine, metoprolol tartrate and salicylic acid; sodium salt (SA), were 
purchased from Sigma (St. Louis, MO, USA).  Ammonium acetate, sodium acetate, 
glacial acetic acid, 85% o-phosphoric acid and HPLC grade acetonitrile were 
purchased from Fisher Scientific (Fair Lawn, NJ, USA).  Ammonium phosphate was 
purchased from Mallinckrodt Chemical Works (St. Louis, MO, USA).  Ringer’s 
solution consisted of 145 mM NaCl, 2.8 mM KCl, 1.2 mM CaCl2 and 1.2 mM MgCl2.  
Artificial gastric solution (pH 2.5-3.0) consisted of 87.4 mM NaCl, 4.0 mM KCl, 0.8 
mM MgSO4, 2.1 mM Na2SO4 and 19.3 mM mannitol.  All chemicals for Ringer’s 
solution and artificial gastric solution were purchased from Sigma or Fisher 
Scientific.  Water for buffer, mobile phase, Ringer’s solution and artificial gastric 
solution was processed through a Labconco WaterPro Plus water purification system 
(18 MΩ/cm) (Kansas City, MO, USA).  Buffer, Ringer’s and artificial gastric solution 
were filtered through a 47 mm, 0.22 µm nylon filter prior to use.  Isoflurane was 
purchased from Fort Dodge Animal Health (Fort Dodge, IA, USA).  Xylazine was 
purchased from Lloyd Laboratories (Shenandoah, IA, USA).  Acepromazine was 
purchased from Boehringer Ingelheim Vetmedica, Inc. (St. Joseph, MO, USA).  
Lactated Ringer’s and 5% dextrose in lactated Ringer’s were purchased from B Braun 
Medical Inc. (Irvine, CA, USA). 
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3.3.2   Microdialysis Probes 
 The linear microdialysis probes used for implantation into the stomach were 
fabricated as previously described in-depth in Section 2.4.1.  All linear probes were 
constructed to a 5 mm effective membrane length.  The construction of vascular 
microdialysis probes for sampling in the blood was previously described in Section 
2.4.2. 
 
3.3.3   Surgical Procedures 
 Female Sprague-Dawley rats (225-300 grams) (Charles River Laboratories, 
Inc., Wilmington, MA, USA) were initially housed with access to food and water in 
temperature and humidity controlled rooms on a 12-hour light/dark cycle.  All 
experiments were in accordance with the Principles of Laboratory Animal Care (NIH 
Publication, no. 85-23, revised 1985) and approved by the University of Kansas 
IACUC committee.  The procedures for ulcer induction, fasting, stomach ligation, 
oral gavage insertion and probe implantation for both normal and ulcerated stomach 
studies were described in-depth in Chapter Two.  At the completion of each 
experiment, the stomach was harvested after animal euthanasia and histology slices 
were processed as described in Section 2.6.1.1.1. 
 For test compounds given intravenously, an incision was made on the skin of 
the inner hind leg to expose the femoral vein/artery/nerve bundle.  Extra connective 
tissue was cleared from the bundle by rubbing the area with a cotton swab applicator 
soaked in saline.  The femoral vein was isolated from the rest of the bundle and a 
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small cut was made on the vein with spring scissors, similar to techniques described 
in Section 2.6.1.2.   MicroRenathane® (MRE-033) (838 µm o.d.; 356 µm i.d.; 
Braintree Scientific, Braintree, MA, USA) tubing was used as the dosing cannula and 
was inserted into the vein through the small cut.  The tubing was tunneled and 
positioned near the heart.  The femoral vein was ligated with 3-0 suture to hold the 
cannula in place.  The cannula was externalized through the incision and the incision 
was closed with wound clips carefully around the cannula.  The exposed end of the 
cannula was connected to a 23-gauge hypodermic needle on a 3 mL syringe of saline. 
 
3.3.4   Microdialysis System 
 Four Hamilton gastight syringes (1 mL) (Reno, NV, USA) were place in a 
CMA model 400 syringe pump (North Chelmsford, MA, USA).  The inlets of the 
microdialysis probes were connected to the syringes and perfused at 1 μL/min.  The 
outlets of the microdialysis probes were placed into BASi Honey Comb fraction 
collectors (West Lafayette, IN, USA) set to collect samples every 15 minutes.  The 
microdialysis samples were collected into 250 μL polypropylene microcentrifuge 
tubes (Fisher Scientific, Fair Lawn, NJ, USA).  A schematic of the microdialysis 
setup is shown in Figure 3.1. 
 
3.3.5   Experimental Design 
 Initially, a “tissue equilibration” period of 1-2 hours was performed where the 
probes were flushed with perfusion fluid.  In the normal stomach studies, 
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 (a) (c) 
(b) 
Figure 3.1.  Microdialysis sampling setup.  (a) Syringe pump to deliver 
perfusate, (b) fraction collector to sample dialysate and (c) temperature 
controller to maintain a 37˚C body temperature.  Arrows indicate the direction 
of perfusate flow. 
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Ringer’s solution was perfused through the mucosa, submucosa and vascular probes 
and artificial gastric solution was perfused through the lumen probe.  In the ulcerated 
stomach studies, Ringer’s solution was perfused through the normal submucosa, 
ulcerated submucosa and vascular probes and artificial gastric solution was perfused 
through the lumen probe.  During the equilibration time, dialysate samples were 
collected. 
 Calibration of the microdialysis probes was performed in vivo by delivery of 
the analyte.  Calibration by this method was described previously in Section 1.4.2.4.  
The perfusate contained either 10 or 25 μM of the analyte to deliver through the 
probe.  The probes were perfused until a steady-state dialysate concentration was 
achieved (~45 minutes).  After the achieved steady-state, five samples were collected 
to determine the delivery extraction efficiency (EEd).  The EEd was calculated using 
Equation 8, as described in Section 1.4.2.4.  The determined EEd values for both the 
normal and ulcerated stomach studies will be discussed in Section 3.4. 
 To prepare the system for dosing, the calibration solution needed to be flushed 
from the microdialysis probes.  This was achieved by perfusion with Ringer’s or 
artificial gastric solution through the probes.  The probes were flushed for 
approximately 1.5 hours and dialysate samples were collected and 
chromatographically analyzed to determine if any analyte remained in the dialysate. 
 When no analyte was detectable in the dialysate, the solution in the stomach 
was removed by pulling on the syringe connected to the gavage tube.  Test compound 
was given by gavage as a bolus dose by replacing the 5 mL syringe containing the 
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removed stomach solution with another 5 mL syringe containing 5 mM analyte 
dissolved in artificial gastric solution.  Three milliliters of the dose was injected into 
the ligated stomach through the gavage tube.  Sampling from the microdialysis probes 
started after correcting for probe dead volume and then microdialysis samples were 
collected for 6 hours post dose from each probe. 
 
3.3.6   Sample Analysis by HPLC-UV 
 All microdialysis samples were analyzed by high performance liquid 
chromatography with ultraviolet detection (HPLC-UV).  Because of the number of 
samples generated for each probe, two analytical systems were used to increase 
sample throughput.  Each system consisted of a Shimadzu LC10-AD pump, a 
Shimadzu SPD-10AV UV-Vis spectrophotometric detector and a Shimadzu SCL-
10Avp system controller (Columbia, MD, USA).  Sample injections were made into a 
Rheodyne model 7125i injector.  The injection was an underfill of 10 μL into a 25 μL 
PEEK sample loop.  Data was acquired using Shimadzu EZ Start version 7.3 software 
for the mucosa and both ulcerated and normal submucosa samples.  Chrom & Spec 
version 1.5 software (Ampersand International Inc., Beachwood, OH, USA) was used 
to acquire data for the lumen and blood samples. 
 The Food and Drug Adminstration (FDA) Guidance of Bioanalytical Method 
Development and a report by Peters et al. were consulted for the acceptance criterion 
for the selectivity, intra-assay precision, linearity and limits of detection (LOD) for 
the HPLC-UV systems [5,6].  The calibration curves were constructed by spiking 
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analyte into Ringer’s or artificial gastric solution in the concentration range of 1-200 
µM, analyzed in triplicate.  Each calibration curve was constructed using Microsoft 
Excel and the method of least squares was applied to determine linearity.  The lumen 
dialysate samples were diluted 1:5 or 1:10 to maintain the samples in the tested 
concentration range.  The results of method validation will be discussed in Section 
3.4.1. 
3.3.6.1   Analysis of Salicylic Acid (SA) 
 Separation of SA was achieved on a Phenomenex Gemini C18 RP column (150 
x 2.00 mm, 5 μm particle).  The mobile phase consisted of 25 mM ammonium 
phosphate, adjusted to pH 2.5 with o-phosphoric acid, with 25% acetonitrile (v/v) [7].  
The flow rate used for this system was 0.35 mL/min.  Detection of SA was performed 
at 300 nm. 
3.3.6.2   Analysis of Caffeine 
 Separation of caffeine was achieved on a Phenomenex Gemini C18 RP column 
(150 x 2.00 mm, 5 μm particles).  The mobile phase for this system was 30 mM 
sodium acetate, adjusted to pH 4.0 with glacial acetic acid, with 10% acetonitrile 
(v/v).  The flow rate used was 0.35 mL/min.  Detection of caffeine was performed at 
280 nm.   
3.3.6.3   Analysis of Metoprolol 
 Separation of metoprolol was achieved on an Agilent Zorbax Bonus-RP 
column (100 x 2.1 mm, 3.5 μm particles).  The mobile phase consisted of 25 mM 
ammonium acetate, adjusted to pH 4.0 with glacial acetic acid, with 10% acetonitrile 
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(v/v).  The flow rate for this system was 0.30 mL/min.  Detection of metoprolol was 
performed at 275 nm.   
 
3.3.7   Data Analysis 
3.3.7.1   Determination of Tissue Concentrations from Dialysate Samples 
 The extracellular concentration (Csample) in each of the studied areas was 
determined by correcting for the extraction efficiency (EE) of the probe from the 
concentration analyzed in the dialysate sample (Cdialysate) as described in Equation 9 
from Section 1.4.2.4.   
3.3.7.2   Concentration-Time Curves 
 Plots of concentration versus time were generated with Microsoft Excel 
(Redmond, WA, USA) and Microcal OriginLab software version 6.0 (Northhampton, 
MA, USA).  To display all probe locations onto a single plot, a semilog plot was 
generated for each study. 
3.3.7.3   Pharmacokinetics Modeling 
 Pharmacokinetics (PK) parameters for each of the compounds in each of the 
studied sites were calculated for further affirmation and interpretation of the 
concentration-time curves.  The pharmacokinetics parameters were calculated using 
WinNonlin version 4.1 software (Pharsight Corporation, Mountain View, CA, USA) 
with confirmation of some results with Microsoft Excel.  
 A catenary compartmental model was used to describe the transport of drug 
from the lumen across the mucosa and submucosa to the blood as described in Figure  
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3.2 [8-10].  Each box represents a compartment (i.e. probe location) and ke represents 
the elimination from each compartment (i.e. transfer to the next compartment). 
 To describe the absorption from the lumen, a one-compartment model with 
bolus input and first order elimination was used.  The equation to describe this model 
is described by Equation 1, which is commonly used to assess disappearance of drug 
from the lumen:  
      
teke
V
DC t
−=)(                             (1) 
 
where C(t) is the concentration at time t, D is the original dose given, V is the volume 
of distribution and ke is the first order transfer rate constant from the lumen [9].  
The modeling for the mucosa, submucosa and blood can be described by a one 
compartment, first-order process shown in Equation 2: 
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 where C(t) is the concentration in the studied area, D is the dose given, V is the 
volume of distribution and ka and ke are the input and output transfer rate constants, 
respectively [9].  The area under the curve (AUC) was determined by the trapezoidal 
rule in all modeled areas.  Statistical analysis of the PK parameters were performed 
with Microcal OriginLab software by the one-way analysis of variance (ANOVA) 
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followed by a Tukey test to determine differences between the studied sites as well as 
between SA, caffeine and metoprolol in each probe location.  A level of p < 0.05 was 
considered statistically different.  
 
3.4   Microdialysis Sampling to Monitor Drug Absorption in the Stomach 
 
3.4.1   HPLC-UV Method Validation 
 Overall, the HPLC-UV systems exhibited acceptable selectivity, linearity and 
repeatability for analysis of dialysate samples in both the normal and ulcerated 
stomach studies.  Figure 3.3 is an example chromatogram from mucosal dialysate 
taken prior to and 15 minutes after a 5 mM oral dose was SA was given by gavage.  
This figure illustrates acceptable system selectivity for SA in the dialysate sample.  
The same selectivity was observed with all test compounds in all probe locations for 
both normal and ulcerated stomach studies.  The calibration curves were linear over 
the range of 1-200 µM with a goodness of fit of 0.99-1.  The intra-assay precision 
was 97% or greater for all calibration curves.  The limits of detection (LOD) for SA, 
caffeine and metoprolol were approximately 200, 100 and 200 nM, respectively, for 
the HPLC-UV system used for mucosa and submucosa of both ulcerated and normal 
tissue.  The LOD for SA, caffeine and metoprolol were approximately 300, 200 and 
600 nM, respectively, for the system used for the lumen and blood samples. 
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Figure 3.3.  Representative chromatogram of SA in mucosa 
dialysate prior to (dotted) and 15 minutes after (solid) a 5 mM oral 
dose of SA.  The concentration of the SA peak is 31 µM. 
3.4.2   Normal Stomach Absorption Studies 
Monitoring drug absorption in the normal stomach was performed in order to 
assess the significance of using microdialysis sampling simultaneously in the stomach 
lumen, mucosa, submucosa and in the blood.  The results of microdialysis sampling 
by this multiple probe approach from orally dosed SA, caffeine and metoprolol to the 
ligated stomach are presented in the following section.  
3.4.2.1   In Vivo Probe Extraction Efficiency 
 The microdialysis probe EEd values for the compounds investigated in each 
probe location are shown in Table 3.2.   
 
 Extraction Efficiency (%) 
Location of 
Probe Salicylic Acid Caffeine Metoprolol 
Lumen 61.8 ± 6.6 (8) 63.0 ± 11.5 (11) 44.2 ± 19.2 (7)  
Mucosa 37.9 ± 13.1 (6) 36.3 ± 6.0 (5) 29.7 ± 8.5 (7) 
Submucosa 32.7 ± 12.4 (9) 39.4 ± 13.6 (14) 30.8 ± 6.5 (7) 
Blood 52.8 ± 12.6 (19) 54.6 ± 13.0 (15) 32.7 ± 7.1 (6) 
 
 Table 3.2.  EEd values for multiple probes in the normal rat stomach.  
Values are average ± standard deviation (n value). 
 
 
In general, EEd values between test compounds within each studied region were 
similar.  Higher extraction efficiencies were generally seen in the lumen and blood.  
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This was expected based on a more hydrodynamic environment around the probes 
implanted in these areas relative to the stomach tissue, where approximately 30% 
delivery was determined for both the mucosa and submucosa.   
3.4.2.2   Salicylic Acid 
 SA has been reported to exhibit rapid absorption in the rat stomach [1].  From 
Table 3.1, the reported pKa and log D (pH 2-3) values are 3.0 and 2.06, respectively 
[2,3].  This indicates that SA is mostly unionized at low pH values (e.g. the stomach 
lumen) and has good lipophilic properties (log P > 0), which are both favorable for 
passive absorption to occur in the stomach [11,12].  
 Figure 3.4 shows the semilog plot of the SA concentration determined in the 
extracellular space as a function of time observed in the lumen, mucosa, submucosa 
and blood.  SA was detected in all of the studied areas in the first 15 minute sample 
taken.  In the lumen, initial high concentrations (mM) were observed that decreased 
over the course of the experiment.  Initially in the first 15 minutes, approximately 100 
µM and 40 µM SA was observed in the mucosa and submucosa, respectively.  
Consistently higher concentrations of SA were observed in the mucosa relative to the 
submucosa in the first hour of sampling.  For both the mucosa and submucosa, the 
peak concentration was reached by the first 15 minute sample.  This indicates that 
during this sampling experiment, the sampling rate would need to be decreased to 
describe the absorption phase into the mucosa and submucosa.  An absorption phase 
was seen in the blood that was most likely due to the time needed for diffusion to 
occur across the stomach tissue and into the systemic circulation. 
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Figure 3.4.  Salicylic acid determined from microdialysis sampling in the 
stomach lumen (■), mucosa (Δ), submucosa (♦) and in blood (○) after a 5 mM 
SA oral dose (n = 4). 
 127
  Overall, the profile of rapid decrease in the lumen, the detection of SA in all 
of the studied areas in the first 15 minutes and the completion of the absorption 
phase in the stomach tissue prior to the first 15 minute sample indicate that orally 
dosed SA exhibited rapid absorption in the rat stomach.  This was consistent with 
the predicted extent of absorption for SA in the stomach.  Although the profiles were 
quite similar, higher concentrations in the mucosa relative to the submucosa were 
observed for the first 1.5 hours of sampling. 
3.4.2.3   Caffeine 
 Caffeine has been reported to exhibit moderate absorption in the stomach and 
was used as a predicted intermediate absorbing test compound [1].  Based on the pKa, 
and log D values of caffeine shown in Table 3.1, caffeine is mostly found in an 
ionized state in the stomach; however, exhibits an equal distribution between both the 
lipophilic and aqueous phases (log D ~ 0) [2,3]. 
 Figure 3.5 shows the semilog plot of the caffeine concentration as a function 
of time after 5 mM caffeine was orally dosed.  As previously seen with SA, caffeine 
was detected in all of the studied areas immediately after administration.  
Concentrations of caffeine in the lumen steadily decreased over the course of the 
experiment, but this decrease was slower than that observed with SA (Figure 3.4).  In 
contrast to SA, an absorption phase was observed in the mucosa and submucosa for 
caffeine.  The profiles in the mucosa and submucosa were identical with peak 
concentrations of approximately 100 µM around 30-45 minutes, whereas small 
differences were detected between the mucosa and submucosa for the first hour of 
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Figure 3.5.  Caffeine determined from microdialysis sampling in the normal 
stomach lumen (■), mucosa (Δ), submucosa (♦) and in blood (○) after a 5 mM SA 
oral dose (n = 4). 
sampling when SA was dosed.  Overall, the comparison of the profiles for both SA 
and caffeine indicate moderate absorption is observed with caffeine.   
3.4.2.4   Metoprolol 
 Metoprolol is reported to have low absorption in the stomach [4].  Based on 
the physicochemical properties of metoprolol, the drug would mostly be in an ionized 
state in the stomach.  Furthermore, the log D (pH 2-3) value indicates that metoprolol 
is more aqueous soluble in the low pH stomach lumen and therefore, would not be 
absorbed to any great extent in the stomach. 
 The semilog plot of the metoprolol concentration as a function of time after 5 
mM metoprolol was orally dosed is shown in Figure 3.6.  A steady concentration of 
metoprolol was observed in the lumen indicating very low absorption of metoprolol 
through the mucosal barrier in the stomach.  Low concentrations of metoprolol (10-15 
µM) were observed in the mucosa while metoprolol was not detectable in the 
dialysate from either the submucosa or the blood.  Overall, these observations are 
again consistent with expectations based on absorption rates relative to SA and 
caffeine.  Differences in the mucosa and submucosa layers are particularly present in 
this study with metoprolol observed in the mucosa and submucosal concentrations 
below the LOD.  
3.4.2.5   Pharmacokinetics Analysis  
 Table 3.3 shows the results from modeling each drug for the lumen, mucosa, 
submucosa and blood.  The transfer rate from the lumen (ke) was faster for SA, then 
caffeine, and the slowest rate for metoprolol.  Additionally, the elimination half-life 
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Figure 3.6.  Metoprolol determined from microdialysis sampling in the stomach 
lumen (■) and mucosa (Δ) after a 5 mM SA oral dose (n = 4).  No detectable 
metoprolol was observed in the submucosa or the blood. 
   ke (hr-1) t1/2 (hr) Cmax (μM) AUC0-6 hr (μM*hr) 
Lumen SA 0.95 ± 0.38 0.42 ± 0.15 3853 ± 670 2227 ± 460 
 Caffeine 0.45 ± 0.054 1.57 ± 0.24 3335 ± 518 7499 ± 1400 
 Metoprolol 0.024 ± 0.018 51 ± 46 3196 ± 832 93043 ± 859 
Mucosa SA 0.19 ± 0.09 4.40 ± 2.23 142 ± 57 125 ± 24 
 Caffeine 0.20 ± 0.17 3.40 ± 1.91 83 ± 43 656 ± 301 
 Metoprolol 0.033 ± 0.018 26 ± 17 14 ± 7 497 ± 110 
Submucosa SA 0.114 ± 0.054 8.63 ± 6.26 48 ± 30 88 ± 25 
 Caffeine 0.156 ± 0.042 4.50 ± 1.12 78 ± 30 460 ± 117 
 Metoprolola - - - - 
Blood SA 0.0024 ± 0.0018 435 ± 383 20 ± 12 6637 ± 4864 
 Caffeine 0.042 ± 0.003 199 ± 15 33 ± 7 1102 ± 851 
 Metoprolola - - - - 
a ( - ) Indicates no analysis was done; concentrations not detected in these sites 
 
Table 3.3.  Pharmacokinetics parameters from the results of microdialysis 
sampling in the lumen, mucosa, submucosa and blood (n = 4).  Values are the 
average ± standard deviation. Statistical analysis by one-way ANOVA 
followed by a Tukey test (p <0.05). 
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(t1/2) increased from 0.42 hours for SA to 51 hours for metoprolol.  Also the area 
under the curve (AUC) values were SA < caffeine < metoprolol, which further 
confirmed a faster absorption of salicylic from the lumen than seen with caffeine and 
metoprolol.  The luminal Cmax values were very similar for all three compounds as the 
same dose was given in these studies. 
The parameters generated for the mucosa and the submucosa were similar not 
only from layer to layer but also statistically similar between SA and caffeine.  This 
similarity is evident in the results from SA and caffeine in the mucosa with ke values 
around 0.20 hr-1 and t1/2 values around 4 hours for both compounds.  These ke and t1/2 
values were also observed in the submucosa when caffeine was dosed.  However, in 
the submucosa after dosing SA, one of the four rats exhibited slower elimination from 
the submucosa (ke = 0.42 hr-1 and t1/2 = 16 hr) resulting in the reported averaged data 
to be different with larger deviations.    No modeling was performed with the 
metoprolol in the submucosa since the concentrations in that tissue were below the 
detection limits of the analytical system. 
Also, since metoprolol concentrations in the blood were below the LOD for 
this study, only SA and caffeine were modeled in the blood.  The rate of elimination 
was slow for both compounds but significantly slower with SA (t1/2 = 435 hrs) than 
with caffeine (t1/2 = 199) (p < 0.05).  Similar Cmax concentrations were observed with 
both compounds with this model, but the AUC for SA was higher than caffeine. 
In conclusion, the predicted absorption trend of SA > caffeine > metoprolol 
was observed by microdialysis sampling in the normal stomach, indicating the current 
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sampling method is successful in monitoring the extent of drug absorption.  For SA 
and caffeine, small differences between drug concentrations in the mucosa and 
submucosa were observed.  With dosed metoprolol, this difference was significant 
since 10-15 µM was observed in the mucosa while metoprolol was below the 
detection limits (200 nM) in the submucosa.  Differences from microdialysis 
sampling in the tissue layers were observed relative to blood, which supports the 
benefits of site-specific monitoring in the stomach tissue.  Overall, the results indicate 
that microdialysis sampling in the stomach by a multiple probe design is a more 
representative sampling method for monitoring drug absorption in the normal 
stomach.  
 
3.4.3   Ulcerated Stomach Absorption Studies 
 As described in Section 2.6.2, a multiple probe microdialysis sampling 
approach was developed to directly compare healthy and diseased tissue in the same 
stomach.  Site-specific ulceration was chemically induced by injection of 20% acetic 
acid (v/v) directly into the submucosa.  Subsequently, microdialysis probes were 
simultaneously implanted in the stomach lumen and submucosa of both ulcerated and 
normal tissue and also in the blood.  As previously described in Section 2.6.2.1, the 
ulcers were measured to be 30-40 mm2 on average, as determined by measuring the 
ulcer index (length x width) [13].  However, due to ulcer perforation, a modification 
to the induction method was performed. Coating the ulcer with lubricant during the 
ulcer induction period decreased perforation, but resulted in smaller ulcers of 
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approximately 15-20 mm2.  This resulted in the ability to control ulcer size for 
monitoring absorption as a function of ulcer size.   
To assess the significance of this microdialysis sampling approach, drug 
absorption of the three previously tested compounds, SA, caffeine and metoprolol, 
was monitored in both the large and small ulcerated stomach using multiple probe 
microdialysis sampling.  The results are presented in the following sections. 
3.4.3.1   In Vivo Extraction Efficiency 
 The microdialysis probe EEd values for each compound studied in each probe 
location for both large and small ulcer stomachs are displayed in Table 3.4.  Even 
though the environment at the ulcerated tissue is affected by the lack of mucosa to 
  Extraction Efficiency (%) 
 Probe 
Location Salicylic Acid Caffeine Metoprolol 
Large Ulcers Lumen 67.5 ± 4.7 42.0 ± 1.6 37.2 ± 5.9 
 Submucosa of 
Ulcer 23.9 ± 11.1 31.7 ± 3.4 19.4 ± 2.7 
 Normal 
Submucosa 23.8 ± 3.2 36.7 ± 8.7 20.7 ± 0.45 
 Blood 40.9 ± 11.3 43.6 ± 2.6 34.8 ± 4.9 
Small Ulcers Lumen 61.3 ± 4.8 39.2 ± 9.2 44.1 ± 15.0 
 Submucosa of 
Ulcer 23.7 ± 11.6 31.7 ± 3.3 33.3 ± 10.4 
 Normal 
Submucosa 14.2 ± 2.4 33.4 ± 8.1 24.3 ± 5.8 
 Blood 40.9 ± 13.2 36.8 ± 12.1 30.1 ± 15.6 
Table 3.4.  EEd values for multiple probes in the ulcerated rat stomach.  
Values are average ± standard deviation (n = 3 for each value for large 
ulcers and n = 4 for small ulcers). 
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protect it from the luminal environment, the EEd values between the normal and the 
ulcerated submucosal tissue are not significantly different indicating the submucosa is 
still intact in the ulcer.  In addition, the EEd values were comparable to what was 
previously determined in the normal stomach studies (Table 3.2).   
3.4.3.2   Salicylic Acid 
 Large Ulcer - Figure 3.7 demonstrates the SA concentration in the stomach 
lumen, in the submucosa of the ulcer and normal tissue and in the blood after a 5 mM 
SA oral bolus dose was administered to a ligated rat stomach with a large gastric 
ulcer.  High concentrations of SA were initially observed in the lumen and the 
concentration decreased over the course of the experiment.  This profile was similar 
to lumen concentrations previously observed in the normal stomach studies (Figure 
3.4).  In addition, an identical profile and the same concentrations were determined in 
the submucosa of the ulcerated tissue relative to the lumen, suggesting that without 
the mucosal barrier present, luminal SA surges non-selectively into the ulcerated 
tissue.  Rapid absorption was also seen in the normal, healthy submucosa and in the 
blood with profiles similar to what was previously observed in the normal stomach 
studies.  By comparison of the submucosal probes, the concentration of drug in the 
ulcerated tissue was significantly higher than that in the normal submucosa, initially 
50-fold higher in the ulcerated tissue which decreased over time to a 2-fold difference 
towards the end of the experiment. 
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Figure 3.7.  Salicylic acid determined from microdialysis sampling in the large 
ulcerated stomach lumen (■), submucosa of the ulcer (Δ), normal submucosa 
(♦) and in blood (○) after a 5 mM SA oral dose (n = 3). 
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Figure 3.8.  Salicylic acid determined from microdialysis sampling in the small 
ulcerated stomach lumen (■), submucosa of the ulcer (Δ), normal submucosa 
(♦) and in blood (○) after a 5 mM SA oral dose (n = 3). 
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            Small Ulcer -   Figure 3.8 shows the SA concentration as a function of time in 
the stomach lumen, submucosa of ulcerated and normal tissue and in blood after a 5 
mM SA oral bolus dose was administered to rats with a small gastric ulcer.  In 
comparison to Figure 3.7, the profiles for the lumen, normal submucosa and blood 
were the same.  The concentrations in the ulcerated tissue were consistently greater in 
this tissue relative to the normal submucosa; however, the difference between these 
two tissue types was significantly greater in the large ulcer than in the small ulcer.  
This suggests that absorption in the ulcerated tissue is a function of ulcer size with 
increased absorption in larger relative to smaller ulcers. 
3.4.3.3   Caffeine 
 Large Ulcer - Figure 3.9 shows the caffeine concentration as a function of 
time after 5 mM caffeine was orally dosed in stomachs with a large ulcer.  Caffeine 
was detected in all of the studied areas in the first 15 minute sample.  The 
concentration of caffeine in the lumen, normal submucosa and blood were similar to 
what was observed previously in the normal stomach studies (Figure 3.5).  Higher 
concentrations of caffeine were observed in the ulcerated tissue relative to normal; 
however, in comparison to SA (Figure 3.7), less absorption was observed in the 
ulcerated tissue relative to normal tissue when caffeine was administered. 
 Small Ulcer - Figure 3.10 shows the PK curves for caffeine in the lumen, 
ulcerated and normal submucosa and in blood after a 5 mM caffeine oral bolus dose 
was administered in rat stomachs with a small ulcer induced.  The profiles in the 
lumen, normal submucosa and blood are similar to what was observed in the large 
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Figure 3.9.  Caffeine determined from microdialysis sampling in the large 
ulcerated stomach lumen (■), submucosa of the ulcer (Δ), normal submucosa (♦) 
and in blood (○) after a 5 mM SA oral dose (n = 3). 
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Figure 3.10.  Caffeine determined from microdialysis sampling in the small 
ulcerated stomach lumen (■), submucosa of the ulcer (Δ), normal submucosa (♦) 
and in blood (○) after a 5 mM SA oral dose (n = 3). 
 
ulcer study (Figure 3.9).  Surprisingly, the average concentration in the ulcerated 
submucosa of the small ulcer was greater than the average concentration in the large 
ulcer.  The probable cause of this is the extremely high concentrations obtained in one 
of the three rats used for this set of experiments in contrast to the remaining two rats, 
which where similar to normal submucosa concentrations were observed.  Figure 3.11 
describes the results of caffeine determined in the ulcerated submucosa from each 
individual rat that contributed to the average data represented in Figure 3.10.  As 
illustrated, one rat had initial concentrations of approximately 3 mM in comparison to 
the other two rats where concentrations of caffeine were observed to be 500 and 10 
µM.  The contribution of the one rat with millimolar concentrations resulted in the 
average biased towards this rat.   
Further investigation of this unexpected increased concentration for this one 
rat was performed by examination of the histology slices of the three rats.  Figure 
3.12 shows the histology results from two of the rats used to generate Figure 3.11.  
Figure 3.12a corresponds to the results depicted as ▲ in Figure 3.11, with high 
concentrations of caffeine observed in the ulcerated tissue.  Figure 3.12b corresponds 
to the results depicted as ○ in Figure 3.11.   As illustrated, when the probe was 
implanted in the ulcerated tissue at a depth closer to the lumen, high concentrations 
were observed in the ulcerated tissue.  However, when the probe was implanted in 
ulcerated tissue closer to the serosal surface (i.e. more superficial), lower 
concentrations were observed.  Also noted was the difference in ulcer thickness.  The 
ulcer in Figure 3.12a is 500 µm in comparison to Figure 3.12b, which is 1100 µm.  
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Figure 3.11.  Individual curves of caffeine concentrations determined in the 
ulcerated submucosa in the small ulcer stomach.  These three curves were 
averaged to give the resulting ulcerated submucosa curve in Figure 3.10. 
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(a) 
0.5 mm 
(b) 
0.5 mm 
Figure 3.12.  Histology slides of two difference ulcers.  (a) Thinner ulcer with 
the probe implanted in the ulcer but closer to the lumen and (b) Thicker ulcer 
with the probe implanted in the ulcer but closer to the serosa.  Images at 20x 
magnification. 
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Therefore, the results obtained suggest that increased concentrations in ulcerated 
submucosa tissue relative to normal tissue were as a result of decreased ulcer layer 
thickness and probe location within the submucosa, but closer to the luminal side. 
3.4.3.4   Metoprolol 
 Large Ulcer - Figure 3.13 shows the plot of metoprolol concentration as a 
function of time after 5 mM metoprolol was dosed orally in a large ulcer study.  A 
steady concentration of drug was observed in the lumen indicating minimal 
absorption from the stomach, as previously characterized in the normal stomach 
studies (Figure 3.6).  The concentration in the submucosa of the ulcerated tissue 
showed concentrations similar to the luminal concentration, and also remained steady 
throughout the course of the experiment.  In contrast to the normal stomach studies 
where metoprolol was not detected in the submucosa or blood, one of the three rats 
used in this study had detectable concentrations of metoprolol in the normal 
submucosa and in the blood.  The other two rats had no detectable metoprolol in 
either the normal submucosa or the blood, similar to the normal stomach studies 
(Figure 3.6).  The histology results gave no indication of differences in this 
experiment relative to other submucosal implantations.  Since metoprolol was only 
detected in these locations in one rat, it was suggested that the appearance of 
metoprolol in these site were not due to natural absorption events, but rather 
experimental errors such as unintentional penetration of the guide needle into the 
mucosal tissue during submucosa probe implantation, which may not be visible 
histologically. 
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Figure 3.13.  Metoprolol determined from microdialysis sampling in the large 
ulcerated stomach lumen (■), submucosa of the ulcer (Δ), normal submucosa (♦) 
and in blood (○) after a 5 mM SA oral dose (n = 3).  Only one of the three rats had 
detectable metoprolol in both the normal submucosa and the blood. 
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Figure 3.14.  Metoprolol determined from microdialysis sampling in the small 
ulcer stomach lumen (■), submucosa of the ulcer (Δ), normal submucosa (♦) after a 
5 mM SA oral dose (n = 3).  Only one of the three rats had detectable metoprolol in 
the normal submucosa.  All rats had no detectable metoprolol in the blood. 
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            Small Ulcer – Figure 3.14 shows the plot of the metoprolol concentration in 
the stomach lumen, ulcerated and normal submucosa and in the blood after a 5 mM 
metoprolol oral bolus dose administered in rat stomachs with small ulcers induced.  
Higher concentrations closer to luminal concentrations were again observed in the 
ulcerated tissue.  As with the large ulcer study, the unpredicted detection of 
metoprolol was observed in the normal submucosa of one of the three rats of this 
study.  In contrast to the previous study, no metoprolol was detected in the blood for 
all experiments.  The histology slides were further investigated to understand the 
source of metoprolol in the normal submucosa.  For the small ulcer study, it is 
suggested that the appearance of metoprolol in the normal submucosa may be the 
result of the proximity of the probe implanted in the normal tissue to the ulcerated 
tissue.  As presented in Figure 3.15, damage to the submucosa extended farther than 
was visible from the serosal side.  In this case, although the probe was implanted in 
normal, healthy submucosal tissue, concentrations detected in the dialysate may be 
influenced by the adjacent ulcerated tissue.  Because the body region of the stomach 
is limited by surface area, it may be challenging to avoid this problem with a multiple 
probe approach within the same tissue layer of the same region of the stomach.  
Although this may explain the appearance of metoprolol in the normal submucosa of 
this study, this does not appear to be the cause of the appearance of metoprolol in the 
large ulcer study.  Further studies to determine the cause of the apparent non-native 
absorption of metoprolol to the normal submucosa would need to be performed. 
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 Figure 3.15.  Histology image showing the proximity of a normal 
submucosal probe to ulcerated tissue.  Image at 20x magnification. 
Normal Probe 
Ulcer Probe 
Damaged Tissue 
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3.4.3.5   Pharmacokinetics Analysis 
 Table 3.5 shows the PK parameters calculated for absorption through large 
ulcers and Table 3.6 shows the PK parameters calculated for the absorption through 
small ulcers.  The transfer rate constants observed in the lumen for both large and 
small gastric ulcers were in the order SA > caffeine > metoprolol (for large ulcers; 
kSA = 0.75; kcaffeine = 0.25; kmetoprolol = 0.15 hr-1 and for small ulcers kSA = 0.75; kcaffeine 
= 0.32; kmetoprolol = 0.021 hr-1). A similar trend was observed in the ke values for the 
ulcerated submucosa for both sizes of ulcers.  Smaller ke values were observed in the 
normal submucosal tissue and very slow elimination was observed in the blood.  In 
most cases, high Cmax values were determined in the lumen and ulcerated submucosa 
(1-3 mM) and lower values were observed in the normal submucosa and in the blood 
(7-45 µM) suggesting differences are seen in the ulcerated submucosa and normal 
submucosa.  However, this is not confirmed statistically because no statistically 
significant differences were observed between the large and small ulcers when 
comparing each studied site for each compound (p < 0.05). 
 In conclusion, microdialysis sampling by a multiple probe approach can 
successfully be used to directly compare normal and ulcerated tissue in the same 
animal.  It was expected that without the protective mucosal barrier present in 
ulcerated tissue, enhanced absorption in the ulcerated tissue would occur.  The results 
of this study were in agreement with enhanced absorption observed in the ulcerated 
tissue relative to normal tissue.  The concentrations in the lumen, normal submucosa 
and blood were comparable with what was determined in the previous study in 
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  ke (hr-1) t1/2 (hr) Cmax (μM) AUC0-6 hr  
(μM*hr) 
Lumen SA 0.75 ± 0.32 0.78 ± 0.11 2123 ± 718 2310 ± 503 
 Caffeine 0.25 ± 0.06 3.02 ± 0.85 3745 ± 85 16318 ± 4483 
 Metoprolol 0.15 ± 0.16 9.85 ± 8.3 2575 ± 
1330 
16395 ± 
12945 
Ulcerated 
Submucosa 
SA 0.57 ± 0.39 1.00 ± 0.39 2241 ± 
2457 
2682 ± 2303 
 Caffeine 0.19 ± 0.02 3.80 ± 0.71 273 ± 132 2063 ± 291 
 Metoprolol 0.18 ± 0.11 4.33 ± 1.97 1830 ± 519 11210 ± 
10125 
Normal 
Submucosa 
SA 0.023 ± 0.016 65 ± 74 38 ± 23 2659 ± 1656 
 Caffeine 0.10 ± 0.12 29 ± 36 57 ± 36 1328 ± 1614 
 Metoprolola 0.35 1.30 11.60 26.25 
Blood SA 0.031 ± 0.023 16.04 ± 2.89 36 ± 17 3069 ± 3045 
 Caffeine 0.0049 ± 
0.0034 
311 ± 300 40 ± 17 23123 ± 
23315 
 Metoprolola 0.186 3.12 3.29 20.5 
a Concentrations only detectable in one of three rats. 
 
 
Table 3.5.  Pharmacokinetics parameters from the results of microdialysis 
sampling from the lumen, submucosa of normal and ulcerated tissue and blood in 
large ulcer studies (n = 3).  Values are the average ± standard deviation. Statistical 
analysis by one-way ANOVA followed by a Tukey test (p <0.05). 
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  ke (hr-1) t1/2 (hr) Cmax (μM) AUC0-6 hr 
(μM*hr) 
Lumen SA 0.75 ± 0.26 0.64 ± 0.48 2121 ± 1776 2452 ± 1919 
 Caffeine 0.32 ± 0.17 2.21 ± 1.55 2968 ± 1189 10909 ± 8908
 Metoprolol 0.021 ± 0.028 213 ± 304 3606 ± 1441 380022 ± 
335039 
Ulcerated 
Submucosa 
SA 0.35 ± 0.23 1.61 ± 0.78 204 ± 132 394 ± 260 
 Caffeine 0.34 ± 0.28 11.41 ± 
11.62 
2000 ± 1689 3822 ± 4239 
 Metoprolol 0.034 ± 0.044 16.15 ± 
21.70 
1774 ± 871 10942 ± 
13714 
Normal 
Submucosa 
SA 0.030 ± 0.019 14.27 ± 8.51 36 ± 14 1067 ± 1388 
 Caffeine 0.051 ± 0.082 102 ± 91 44 ± 18 3300 ± 2281 
 Metoprolola 0.47 1.93 20 155 
Blood SA 0.0074 ± 
0.0093 
409 ± 543 22 ± 14 1420 ± 172 
 Caffeine 0.025 ± 0.021 99  ± 84 45  ± 2 4341 ± 120 
 Metoprololb - - - - 
aConcentrations only detectable in one of three rats. 
b ( - ) indicates no modeling done since no concentrations were detected. 
 
  
Table 3.6.  Pharmacokinetics parameters from the results of microdialysis 
sampling from the lumen, submucosa of normal and ulcerated tissue and blood in 
small ulcer studies (n = 3).  Values are the average ± standard deviation. 
Statistical analysis by one-way ANOVA followed by a Tukey test (p <0.05). 
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normal stomachs.  Additionally, from these studies, it was concluded that absorption 
is a function of ulcer size in that larger ulcers resulted in more drug concentration 
determined in the tissue.  However, larger variations were observed with this study 
relative to the normal stomach studies, which may be a function of probe location 
within the ulcer, the ulcer layer thickness and proximity of probes implanted in 
different tissue types.  
  
3.4.4   Submucosal Probe Implantation Effects on Absorption 
 The submucosa houses the major blood vessels responsible for systemic 
uptake of drugs dosed to the GI tract.  During the microdialysis probe implantation 
procedure, there is some damage to small blood vessels adjacent to the probe.  
Although precautions are taken to avoid probe implantation through blood vessels 
that are visual from the serosal side of the stomach, small blood vessels can be torn 
during implantation and small amounts of blood pooling in the submucosal layer can 
occur.  Histologically, this is shown as dark red areas in the submucosa.  Since probe 
implantation causes local damage to the blood vessels, studies were performed to see 
if probe implantation results in changes to overall systemic drug absorption.  This was 
assessed by comparing drug concentration in the blood of rats with and without linear 
probes implanted into the submucosa.  In one set of animals, a linear probe was 
implanted into the stomach lumen and a vascular probe was implanted in the blood.  
The mucosa and submucosa remained intact without any probes implanted to perturb 
the tissue.  Caffeine was dosed orally (5 mM bolus dose via gavage tube) to the 
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Figure 3.16.  Submucosal probe implantation effects on drug 
absorption.  Triangles and squares are lumen and blood caffeine 
concentrations, respectively.  Open symbols are experiments from the 
two probe design (n = 2) and closed symbols are from the four probe 
design (n = 4). 
anesthetized rat with stomachs ligated at the cardiac and pyloric sphincters to contain 
the dose in the stomach.  The results from this study were compared with experiments 
where linear microdialysis probes were implanted in the stomach lumen, mucosa and 
submucosa and a vascular probe implanted in the blood with the same 5 mM caffeine 
oral dose to the ligated stomach (Figure 3.5).  The results of the two groups of 
animals were compared and are shown in Figure 3.16.  Even though there is local 
blood vessel damage in the submucosa during probe implantation, the results of these 
experiments indicate that implanting probes in the mucosa and submucosa do not 
affect the overall systemic drug absorption of caffeine into the systemic circulation.  
This was shown in the similarities of the blood concentrations.  The concentrations in 
the lumen were used as a marker to indicate that the same dose was given for both 
sets of experiments. 
 
3.4.5   Bi-directional Flow of Analyte Through the Tissue 
 As previously mentioned, it is widely accepted that drug transport occurs from 
the lumen, across the mucosa and into the submucosa for systemic uptake.  
Preliminary studies using microdialysis sampling in the stomach were performed to 
test the bi-directionality of the stomach tissue.  For this research, high concentrations 
(5 mM) were dosed to the lumen.  Therefore, the observed luminal concentrations 
would mask small changes in concentration due to the return of analyte to the lumen.  
The bi-directional transport of analyte across the stomach tissue was studied by 
Doluisio et al. [14].  It was reported that an intravenous (i.v.) dose of 1.5-5 times the 
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amount placed in the lumen resulted in no more than 5 % of the i.v. dose detected in 
the lumen by the in situ closed loop method.   
 To test the significance of bi-directional flow of analyte in the stomach, linear 
microdialysis probes were positioned in the stomach lumen and submucosa and a 
vascular probe was implanted in the jugular vein.  A cannula was inserted into the 
femoral vein and a 20 mg/kg i.v. bolus dose of SA in saline was administered through 
the cannula.  This dose was 2 times the oral dose of SA given in the orally dosed 
experiments, as will be discussed further in the next section.  Table 3.7 shows the 
tabulated results of drug concentration calculated in the lumen, submucosa and blood 
post dose.  
 
 Concentration of SA (µM) Ratio (%) 
Time 
(min) 
Lumen Submucosa Blood Lumen:Dose 
 
Submucosa:Dose 
15 1.03 68.60 238.27 0.016 10.98 
30 BLQ 69.73 208.65 ND 11.16 
45 BLQ 77.87 205.41 ND 12.47 
60 BLQ 78.14 189.54 ND 12.51 
75 BLQ 75.71 179.37 ND 12.12 
90 BLQ 72.61 184.00 ND 11.63 
   Average ND 11.81 
BLQ = below the limits of quantitation             ND = not determined 
 
Table 3.7.  Microdialysis sampling study of bi-directional flow of SA across 
the stomach tissue after a 20 mg/kg i.v. bolus SA dose. 
 
As demonstrated, this study was in support of less than 5% of the i.v. dose detected in 
the lumen, but also demonstrated 12% of the dose was present in the submucosa.  The 
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results indicate that SA will diffuse from the blood into the stomach tissue.  It is 
suggested that SA would penetrate into the lumen, but would be diluted to 
undetectable concentrations by the gastric solution.  Linear probes were not 
successfully implanted in the mucosa for this study.  However, based on the results 
from this study, it is predicted that a similar appearance of SA would be observed in 
the mucosa as was demonstrated in the submucosa since no significant transport 
barrier is present between the mucosa and submucosa.  Further studies to determine 
the significance of bi-directional drug transport across the mucosa would be to 
include linear probes in the mucosa to further assess this importance. 
 
3.4.6   Advantages and Disadvantages to this Approach 
 Overall, microdialysis sampling by a multiple probe approach to monitor drug 
absorption was successful for monitoring concentrations in the stomach lumen, 
mucosa, submucosa and blood in the normal, healthy stomach and in the lumen, 
submucosa of both ulcerated and healthy tissue and finally in the blood of an 
ulcerated stomach model.  The advantages and disadvantages of this approach will be 
discussed in the following sections. 
3.4.6.1   Advantages 
 Since the stomach is a heterogeneous tissue, the ability to site-specifically 
monitor the mucosa and submucosa simultaneously with this microdialysis sampling 
was achieved.  This four-probe approach of microdialysis sampling simultaneously in 
the stomach lumen, mucosa, submucosa and in blood has not previously been 
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reported in literature and provides more accurate sampling in the stomach.  The 
microdialysis probes are sufficiently small (350 µm o.d.) to be implanted in the 
mucosa and submucosa separately.  This is an improvement over the current use of 
microdialysis sampling in the stomach, which is only performed in the submucosa.  
Typically, blood sampling is used to monitor drug absorption in the GI tract.  The 
results of this research indicate differences in tissue concentration relative to blood 
were observed, which strengthens the need for this sampling technique to evaluate the 
drug concentrations in the stomach tissue.   
 In addition, differences in normal and diseased tissue can be observed with 
microdialysis sampling.  A four-probe microdialysis sampling approach in the 
stomach lumen and submucosa of normal and ulcerated tissue and in the blood has 
not been previously reported in literature.  Traditionally, excised ulcerated stomach 
tissues would be compared to control normal excised stomach tissue from a different 
animal.  By monitoring diseased and healthy tissue of the same stomach, inherent 
biological variation is decreased by using one animal for the entire sampling period, 
whereas excised tissue studies require multiple animals and therefore results in 
increased study variability. 
3.4.6.2   Disadvantages 
 This multiple probe approach to monitoring drug concentrations in the 
stomach also has limitations.  The stomach tissue layers are approximately 500-700 
µm thick.   Therefore, a “skilled” surgeon is required to implant microdialysis probes 
into each tissue layer.  Also, because of the limited surface area of the stomach, 
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proper probe spacing to limit cross-communication of tissue types may be 
challenging.  Additionally, although the this approach to microdialysis sampling was 
demonstrated to be successful for in-depth drug absorption studies for SA, caffeine 
and metoprolol, this technique is not suitable for quick drug screening.  
 In the current ulcerated model, the ulcer must be visible on serosal surface to 
successfully implant a microdialysis probe into the intact tissue.  The current ulcer 
induction model results in the increased probability of ulcer perforation because the 
muscularis externa can also become damaged during ulcer induction.   This ulcer 
induction method resulted in ulcers that vary in tissue thickness and size, which along 
with probe location in the tissue caused increased variability within the study; 
however, this variability did not affect the ability to compare ulcerated and normal 
tissue in the same stomach.  Even though there are some limitations with this 
technique, overall, this multiple probe approach is successful in providing more 
detailed information relative to traditional techniques of sampling from the stomach. 
 
3.5   Conclusions 
 
 Overall, microdialysis by a multiple probe approach can be used to 
successfully monitor drug concentrations simultaneously in the stomach lumen, 
mucosa, and submucosa and in blood.  By dosing test compounds with known 
degrees of absorption in the rat stomach, the method followed the expected trend of 
SA exhibiting rapid absorption, caffeine resulting in moderate and metoprolol 
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demonstrating low absorption in the stomach.  Small differences were observed 
between the mucosa and submucosa for dosed SA and caffeine, but a greater 
difference was observed in metoprolol with concentrations of 10-15 µM in the 
mucosa and no detectable metoprolol in the submucosa (LOD 200 nM).  In addition 
to monitoring different tissue layers, this multiple probe approach could successfully 
be utilized to directly compare normal and ulcerated tissue.  In general, drug 
absorption was increased in the ulcerated tissue relative to normal tissue.  This 
increase was determined to be a function of ulcer size and thickness and probe 
location within the ulcer. 
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CHAPTER FOUR 
 
Summary and Future Directions of Multiple Probe Microdialysis  
Sampling in the Stomach 
 
 
4.1   Summary of the Presented Research 
 
 Due to the heterogeneity of the stomach tissue, microdialysis sampling by 
implantation of a single probe into a tissue cannot accurately reflect sampling from 
the stomach.  Observable differences between the tissue layers would be expected.  
Current uses of microdialysis sampling in the stomach include implanting a probe in 
the submucosa and monitoring analytes such as histamine release from the ECL cells 
in the mucosa [1-4].  Multiple probe microdialysis sampling in the mucosa and 
submucosa simultaneously would serve as an improvement to current methods of 
microdialysis sampling in the stomach.  In addition, the use of a multiple probe 
approach with microdialysis sampling would enhance studies by allowing for the 
direct comparison of different tissue types in the same animal.  This would effectively 
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reduce biological variability so small differences between these tissue types may be 
observed.   
 
4.1.1   Implantation of Multiple Microdialysis Probes in the Rat Stomach 
 Implantation in the Normal Stomach.  Chapter Two presented a multiple 
probe approach of microdialysis sampling in the normal stomach to sample different 
tissue layers.  This was achieved by implanting probes simultaneously in the stomach 
lumen, mucosa and submucosa and in the blood.  Initially, it was determined that the 
average tissue layer thickness of the mucosa and submucosa in the female Sprague-
Dawley rat stomach were 700 and 500 µm, respectively.  Therefore, it was 
established that the small outer diameter microdialysis probe (350 µm) would be 
sufficient to achieve sampling from separate layers once implanted into each layer.  
Successful methods of implanting linear microdialysis probes in the stomach lumen, 
mucosa and submucosa were achieved by the use of a 25-gauge hypodermic needle 
that served as a guide.  Due to the sub-millimeter thickness of each tissue layer, the 
needle was implanted into the intact tissue using the visual difference of the 
implanted guide into each layer.  Since probe implantation in the mucosa has not 
previously been reported in literature, tissue response to probe implantation was 
studied by harvesting stomach tissue at different time points and histologically 
examining tissue slices stained by hematoxylin and eosin.  Over a 12-hour period, no 
significant tissue response to probe implantation was observed in both the mucosa 
and submucosa.  More importantly, the histology results confirmed that methods of 
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simultaneously implanting microdialysis probes in the normal stomach lumen, 
mucosa, and submucosa and in blood were successful by this implantation method. 
 Implantation into the Ulcerated Stomach.  In addition to multiple probe 
implantation procedures in the normal stomach, Chapter Two presented methods of 
multiple probe microdialysis sampling in the ulcerated stomach to sample different 
tissue types.  This was achieved by implanting probes into the stomach lumen, 
submucosa of both ulcerated and normal tissue and in the blood of rats with a gastric 
ulcer induced.  Induction was achieved by injection of 20% acetic acid (v/v) into the 
stomach submucosa [5].  The resulting ulcers were visible on the serosal side and had 
an ulcer index of approximately 30-40 mm2.  However, due to the fragile nature of 
the tissue, perforation of the ulcer upon probe implantation occurred with this 
method.  To circumvent perforation, the ulcer was coated with lubricant during the 
induction and formation period.  With the lubricant, less perforation of the ulcer was 
observed, but the ulcer index values decreased to 15-20 mm2.  The procedure for 
probe implantation into the ulcerated tissue was similar to described methods in the 
normal stomach.  Examination of the tissue slices indicated that overall, microdialysis 
probes were successfully implanted simultaneously into the stomach lumen and 
submucosa of both ulcerated and normal tissue and in the blood. 
 
4.1.2   Multiple Probe Microdialysis Sampling to Monitor Drug Absorption in 
the Stomach 
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 Absorption in the Normal Stomach.  Chapter Three presented studies to test 
the significance of a multiple probe microdialysis sampling in different tissue layers 
by monitoring drug absorption in vivo in the rat stomach.  Salicylic acid (SA), 
caffeine and metoprolol were chosen as test compounds whose extent of absorption in 
the rat stomach have previously been studied [6,7].  The results of microdialysis 
sampling in the stomach were compared with the predicted absorption rates to 
determine the utility of this sampling technique.  A 5 mM dose of test compound 
dissolved in artificial gastric solution was given to the anesthetized rat by oral gavage 
to fasted, ligated rat stomachs with microdialysis probes implanted in the stomach 
lumen, mucosa and submucosa and in blood.  Concentrations-time curves and 
pharmacokinetics (PK) modeling from each probe location indicated that the expected 
trend of absorption, SA > caffeine > metoprolol, was observed by this multiple probe 
approach.  Analytes were observed in all of the studied areas in the first 15 minute 
sample taken from all probe locations when SA and caffeine were dosed.  Metoprolol 
in the submucosa and blood were below the limits of detection (LOD) for the 6 hour 
sampling period.  Consistently higher concentrations were observed in the mucosa 
relative to the submucosa.  This was particularly evident in the metoprolol studies 
were detectable concentrations were observed in the mucosa but concentrations were 
below detection limits in the submucosa.  In all studies, the determined concentrations 
in both the mucosa and submucosa were significantly different than concentrations 
observed in the blood, which strengthens the application of this site-specific 
technique over traditional methods to study drug absorption such as blood sampling.  
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Based on the results, it was concluded that this multiple probe approach was 
successful to monitor drug concentrations in the different stomach tissue layers in the 
normal stomach. 
 Ulcerated Stomach Absorption.  In addition to drug absorption studies in the 
normal stomach, Chapter Three presented research to study the significance of a 
multiple probe approach to directly compare drug absorption in both ulcerated and 
normal tissue of the same rat when both large and small gastric ulcers were induced.  
The previously dosed compounds SA, caffeine and metoprolol, were used for the 
ulcerated stomach studies to compare the results to the normal stomach studies.  The 
same trend in the extent of absorption was observed in these studies showing rapid 
absorption of SA, moderate absorption of caffeine, and low absorption of metoprolol 
for both large and small ulcerated stomach studies.  Overall, more absorption was 
observed in the ulcerated tissue relative to the normal submucosal tissue.  
Concentrations observed in the lumen, normal submucosa and blood were identical to 
what was observed in the normal stomach studies.  Differences were also observed 
when comparing large and small ulcerated tissue.  Higher drug concentrations were 
generally observed in the large ulcerated tissue relative to the small ulcer suggesting 
absorption is a function of ulcer size with increased absorption in larger ulcers.  In 
general, more variation was observed with the ulcerated stomach studies relative to 
normal stomach studies, which was concluded to be a factor of ulcer size, tissue 
thickness and probe location within the ulcer.  Even with this increased variation, 
overall, the results indicate that this multiple probe microdialysis approach was both 
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successful and significant to directly monitor drug absorption in ulcerated and normal 
tissue. 
 
4.2   Future Directions of This Research 
 
4.2.1   Continuation of Drug Absorption Studies in the Stomach 
 Future work of this research includes the continuation of the current studies by 
extending the range of analytes tested.  Currently, three test compounds with different 
degrees of passive absorption in the stomach have been studied with this technique.  
To illustrate the use of microdialysis sampling in stomach drug absorption studies, the 
range and classes of compounds would need to be extended.  This may aid in the 
determination of why caffeine absorption in the ulcerated tissue did not exhibit the 
expected trend of significantly increased absorption in the ulcerated tissue.  By 
advancing this technique to several other analytes, it may be determined if the 
majority of moderate absorbing compounds exhibit the same absorption 
characteristics as caffeine. 
 Along with dosing compounds individually in drug development studies, this 
sampling technique can be further used to monitor drug concentrations in the stomach 
tissue in the presence of another drug or study the effects of excipients on drug 
absorption for formulation studies. 
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4.2.2   Extension of a Multiple Probe Approach in the Intestines 
 It is well known that absorption primarily occurs in the small intestines, 
therefore, extension of microdialysis sampling as a site-specific technique in the 
intestines would be valuable in drug absorption studies.  Based on the anatomy of the 
small intestines, possible challenges with the implantation of microdialysis probes in 
the intestines relative to the stomach are the increased number and amplitude of the 
folds and microvilli present in the mucosa of the intestines and also the decreased 
surface area available for probe implantation.  Initial optimization of a microdialysis 
sampling in the stomach indicates that transition of a similar approach would be 
successful.  Ultimately, microdialysis probes can then be implanted in several 
locations throughout the GI tract to assess the extent and location of drug absorption.  
This offers a more complete understanding of drug absorption during development 
studies relative to the traditional sampling methods described in Chapter One. 
 
4.2.3   Utilization of Multiple Probe Microdialysis Sampling in Awake Animals 
 The drug absorption studies presented in this research were performed on 
anesthetized rats.  This is not representative of circumstances under which drugs are 
administered.  Future use of this multiple probe microdialysis sampling technique into 
awake, conscious animals would augment the utility of the technique.  In awake 
animal studies, the added dimension of physiological factors affecting drug 
absorption (e.g. presence of food and transit times) would be challenging in the 
assessment of drug absorption, but would be more representative of drug absorption 
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in the GI tract.  Awake animal studies increases the chance of tissue tearing at the 
probe implantation site due to animal movement and peristalsis of the GI tract; 
however, studies of microdialysis sampling in stomach submucosa of awake rats has 
previously been achieved [2]. 
   
4.2.4 Enhancement of the Current Uses of Microdialysis Sampling in the 
Stomach 
 As previously mentioned in Section 4.1, microdialysis sampling has been 
performed in the stomach to monitor ECL cell histamine release in the mucosa by a 
probe implanted into the submucosa.  To more accurately quantify histamine 
concentrations in the stomach tissue and circumvent the issue of degradation of 
histamine during diffusion to the sampling site, the methods of multiple probe 
microdialysis sampling presented in this research can be used.  The results from this 
method can be compared to previous histamine studies with the addition of 
information from sampling in the mucosa layer.   
 
4.2.5   Examination of Endogenous Compounds in Relation to GI Disease 
 Microdialysis sampling in the GI tract may be used to study analytes involved 
in ulcer formation in both gastric and duodenal ulcers.  With microdialysis probes 
implanted in the mucosa and submucosa, an enhanced understanding of the chemistry 
involved during ulcer formation may be possible.  Due to the potential of sampling 
for extended time periods, microdialysis sampling may be used to monitor analytes in 
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ulcerated tissue over the course of weeks from the same animal to improve the 
understanding of the mechanisms involved during ulceration and healing.  In 
addition, microdialysis sampling is useful for sampling several analytes 
simultaneously within the tissue for a comparison of several markers of disease.  
Finally, this sampling technique may be extended to study the underlying 
mechanisms involved in other diseases of the GI tract. 
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